Podcasts about castle biosciences

Dr. Naresh Gunaratnam interviews Dr. Deepti Mehtani, vice president of clinical solutions for NextGen Healthcare, about its recently launched Gastro Suite, which brings gastro-specific workflows to the NextGen electronic health record to streamline repetitive tasks, deliver faster insights, and support an enhanced patient experience. The suite is easily integrated with other solutions from NextGen Healthcare, enabling hands-free mobile documentation with NextGen Ambient Assist, enhanced patient engagement with the NextGen Closed Loop Patient and Practice Experience, billing automation, cloud hosting, and advanced interoperability. Join Dr. Gunaratnam and Dr. Mehtani as they explore what independent GI practices should be considering when looking for an industry partner to help improve their data and technology platforms. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 78, presented by TissueCypher from Castle Biosciences

Dr. Lisa Mathew interviews Dr. Brittany Panico, a rheumatologist in Colorado Springs who recently wrote an op-ed calling for reforms to the 340B program to require more transparency and reporting on how 340B discounts are passed on to patients. The 340B Program is a federal drug pricing program that allows certain hospitals and clinics to buy medications at steep discounts to support medication access for underserved patients, with the expectation that these savings would be passed on to patients. But critics argue that the program's growth has led to unintended consequences, such as market consolidation. And some studies suggest that 340B discounts may not translate into increased care or lower costs for vulnerable populations. Join Dr. Mathew and Dr. Panico as they discuss Dr. Panico's experience as an employed physician in a 340B hospital system and as an independent physician, and how the lack of oversight in the program may be making it harder for specialists to deliver the best patient care. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 77, presented by TissueCypher from Castle Biosciences

Dr. Lisa Mathew interviews Vetri Venthan Elango and Dr. Renu Dhanasekaran MD PhD, the founders of Arithmedics, a company that uses generative AI and data intelligence to reduce administrative time and costs for providers. Arithmedics uses generative AI and data intelligence to reduce billing mistakes and claim denials. Its software generates and explains codes to streamline the billing process and uses data from completed claims to reduce future denials. Join Dr. Mathew, Dr. Elango and Dr. Dhanasekaran as they discuss what physicians need to understand about implementing AI platforms for administrative tasks such as billing and coding. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 76, presented by TissueCypher from Castle Biosciences

Episode 31, In this episode, we look at redefining Gastroenterology: Mentorship, Innovation, and the Future of Interventional Endoscopy with Dr. Srinadh Komanduri Episode Summary: In this episode of The Interventional Endoscopist, host Dr. Mankanwal Sachdev reconnects with his longtime mentor, Dr. Srinadh Komanduri of Northwestern University. The two dive into Dr. Komanduri's unique training path, his role in building Northwestern's interventional endoscopy program, and how the field of GI is shifting away from traditional definitions toward a more therapeutic and innovation-driven future. The conversation covers the launch of Northwestern's system-wide GI integration, the impact of tools like TissueCypher for risk stratification in Barrett's esophagus, and the critical need to rethink GI fellowship structure. They also touch on barriers to technology adoption, the role of AI in operational efficiency, and how innovation can (and must) scale beyond a few experts to change care across systems. Topics Covered: Dr. Komanduri's mentorship and hybrid fellowship experience Building an interventional GI network across 11 hospitals Moving beyond the “general GI” label Risk stratification and innovations in Barrett's esophagus care AI's role in reducing burnout and boosting clinical efficiency Future models for GI training and specialization Barriers to adoption and how to drive systemic innovation Sponsored by: Castle Biosciences – maker of TissueCypher®, a test to predict esophageal cancer risk in Barrett's esophagus

Dr. Lisa Mathew interviews Gary Trendel, vice president of Endoscopy Solutions Ecosystem and Dr. Ruhy Patel, Medical and Scientific Affairs lead for the Endoscopy Solutions Ecosystem and Digital Units at Olympus. Odin Medical, an Olympus company, recently received 510K clearance from the U.S. Food and Drug Administration for the first cloud-based Artificial Intelligence technology designed to assist gastroenterologists in detecting colorectal polyps during colonoscopy procedures. The CADDIE, or computer-aided detection (CADe) device, works by analyzing colonoscopy video in real-time and using visual markers to alert the endoscopist to the potential presence of polyps. A prospective, multi-center randomized controlled trial successfully demonstrated the efficacy and safety of the CADDIE device, underscoring its potential to enhance detection capabilities and patient care without increasing procedural risks or duration. Join Dr. Mathew, Mr. Trendel, and Dr. Patel as they discuss the potential for AI in improving patient care, and what independent GI physicians should understand about AI platforms that assist in detecting polyps during colonoscopy. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 75, presented by TissueCypher from Castle Biosciences

April is Esophageal Cancer awareness month. Dr. Parikh interviews fellow gastroenterologist, Dr. George Sun. They discuss the epidemiology, risk factors, and symptoms of esophageal cancer before briefly providing an overview of treatment modalities. This episode is brought to you by Castle Biosciences, maker of TissueCypher, a test designed to predict the risk of esophageal cancer in patients with Barrett's esophagus.

Dr. Lisa Mathew interviews Jeff Glueck, co-founder and CEO of Salvo Health, a technology company that partners with GI practices to support patients with chronic GI conditions through a virtual clinic experience using a multi-disciplinary care team. Salvo Health's framework seeks to restore balance and improve chronic symptoms by considering the interconnected roles that the mind, body and gut play in a person's health. Join Lisa and Jeff as they discuss what GI physicians should consider in partnering with technology platforms that provide cross-functional care to their patients. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 74, presented by TissueCypher from Castle Biosciences

Dr. Lisa Mathew interviews Dr. Vijay Yajnik, vice president and head of U.S. Medical, Gastroenterology, at Takeda about how the prevalence of eosinophilic esophagitis (EoE) is increasing, and evidence is growing that EoE is not a rare disease, but an underdiagnosed one. Approximately one in 2000 people in the U.S. live with EoE, and the incidence and prevalence of eosinophilic esophagitis have steadily increased over time. Join Dr. Mathew and Dr. Yajnik as they explore progress that has been made in diagnosing and treating EoE, and some recent studies that could influence patient care. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 73, presented by TissueCypher from Castle Biosciences

I am excited to share insights from the Interventional Endoscopist podcast featuring Dr. Sachin Wani! The discussion centered on Barrett's esophagus, and strategies to improve detection and risk stratification Key takeaways: • The rising incidence of esophageal adenocarcinoma makes early detection crucial. Yet, survival rates remain low, highlighting the need for improved strategies • PEEC and PEEN underscore the issue of missed lesions during endoscopy, emphasizing the need for high-quality exam. • PEEC (postendoscopy esophageal adenocarcinoma) refers to cancer detected before the next recommended surveillance endoscopy in patients with non-dysplastic Barrett's esophagus.  • PEEN (postendoscopy esophageal neoplasia) is a composite endpoint of high-grade dysplasia or cancer detected before the next recommended surveillance exam • A high-quality endoscopic exam is paramount, including meticulous inspection, standardized classification, and advanced imaging techniques like chromoendoscopy.  • A 10-step approach to a high-quality exam includes identifying landmarks, spending adequate time inspecting the Barrett's segment, cleaning the distal esophagus, and using high-definition white light endoscopy and virtual chromoendoscopy • While the Seattle biopsy protocol is standard, it has limitations due to sampling errors • WATS (Wide Area Transepithelial Sampling) can enhance neoplasia detection as an adjunct to the Seattle protocol by sampling the entire Barrett's segment. • AI (artificial intelligence) holds promise for lesion detection, improved diagnostic accuracy, and quality assessment of endoscopic exams. AI platforms may help identify visible lesions and predict histology, as well as assess the quality of the endoscopic examination. • The Tissue Cypher test can aid in risk stratification by analyzing biomarkers to predict the risk of progression to high-grade dysplasia. It can also predict prevalent high-grade dysplasia or cancer.  • Dr. Wani also shared his journey into medicine, influenced by his family, and the challenges faced by foreign medical graduates. A key message was the importance of continuous improvement in endoscopic techniques and the integration of new technologies to combat esophageal adenocarcinoma   This episode was sponsored by Castle Biosciences the makers of the TIssue Cypher Test.

Dr. Michael Weinstein interviews Dr. Ali Rezaie, a GI physician-scientist who specializes in microbiome research and gastrointestinal motility disorders. His recent study, which won an award at ACG, showed that a new elemental diet from mBIOTA Labs can significantly improve patient compliance. The study assessed mBIOTA Elemental, a palatable elemental diet designed to address the barriers of poor taste and low adherence associated with traditional elemental diets. Participants using mBIOTA Elemental had complete compliance throughout the two-week therapy, a critical outcome when managing gastrointestinal disorders such as Small Intestinal Bacterial Overgrowth (SIBO), Inflammatory Bowel Disease (IBD), and other complex GI conditions. Join Dr. Weinstein and Dr. Rezai as they explore how new innovations in elemental diets can help support patients with specific GI conditions and needs. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 72, presented by TissueCypher from Castle Biosciences

Dr. Michael Weinstein interviews Dr. Larry Kosinski about new data from SonarMD describing the association between anxiety and increased risk for flares and higher disease severity in inflammatory bowel disease (IBD), and emphasizing the importance of integrating mental health support within value-based care models for IBD management. According to the study, Patients with anxiety symptoms were significantly more likely to have high disease severity, and over a six-month follow-up, patients with anxiety exhibited a nearly doubled flare rate. The study suggests that mental health factors like anxiety play a critical role in the clinical course of IBD and that by identifying and addressing psychological contributors, value-based care models can be refined to better support patients with chronic digestive diseases. Join Dr. Weinstein and Dr. Kosinski as they explore the importance of a multidisciplinary approach to IBD management and what GI physicians can do to ensure that their patients have the resources they need. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 71, presented by TissueCypher from Castle Biosciences

In episode 29 of the Interventional Endoscopist Podcast, join us for an insightful conversation with Dr. Legett from the Mayo Clinic, Rochester. We delve into his extensive experience in treating esophageal disorders, focusing on Barrett's esophagus. Dr. Legett shares his journey and training at Mayo Clinic, highlighting his expertise in leveraging artificial intelligence and precision medicine, such as the TissueCypher test, to enhance early detection and management of Barrett's esophagus and esophageal cancer. The episode explores the challenges of diagnosing dysplasia, the transformative potential of AI in standardizing pathology, and improving patient care. Additionally, we discuss the role of molecular profiling in risk stratification and emphasize the critical need for ongoing research to optimize management strategies for Barrett's esophagus. This episode is proudly sponsored by Castle Biosciences, the innovators behind TissueCypher, a test designed to predict esophageal cancer risk in patients with Barrett's esophagus.

In this Gut Doctor episode, Dr. Parikh takes on the patient role as PA Sarah Enslin discusses diagnosis and management of Barrett's esophagus. Sarah Enslin is a physician assistant at the University of Rochester Medical Center and Vice Chair of American College of Gastroenterology's Advanced Practice Provider committee. Today's episode is brought to you by Castle Biosciences, maker of TissueCypher, a test designed to predict the risk of esophageal cancer in patients with Barrett's esophagus.

Host Dr. Lisa Mathew interviews Kathleen Teixeira, vice president of public policy and advocacy for the American Gastroenterological Association. Lisa and Kathleen discuss what policies will be in play in 2025 and how GI physicians can get involved to advocate for their patients and their practices. Join Lisa and Kathleen as they explore how physicians can get involved in shaping the policies that will affect patient care and practice management with the new Congress and Administration. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 69, presented by TissueCypher from Castle Biosciences

Kevin Harlen interviews Laura Wingate, chief education, support, and advocacy officer with the Crohn's & Colitis Foundation about a recent survey which shows that more than 40 percent of patients with inflammatory bowel disease (IBD) have made significant financial trade-offs to afford their healthcare. The survey, published in Inflammatory Bowel Diseases, included responses from more than 2,200 IBD patients and caregivers, who highlighted persistent challenges. Among respondents, 30 percent reported giving up vacations or major household purchases, 22 percent increased their credit card debt, and 21 percent cut back on essential items such as food, clothing, or basic household items. Join Kevin and Laura as they explore what can done to ensure that IBD patients can access the medications they need without undue financial hardship. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 69, presented by TissueCypher from Castle Biosciences

Dr. Fred Rosenberg interviews Dr. Ruchi Mathur, director of the Diabetes Program in the Division of Endocrinology, Diabetes and Metabolism and an endocrinologist at the Weight Loss Center, at Cedars-Sinai. Cedars-Sinai recently released a study which found that patients who take a class of widely prescribed medications (GLP-1) to manage diabetes and obesity may require extra preparations before undergoing endoscopic procedures. Join Dr. Rosenberg and Dr. Mathur as they explore how gastroenterologists can advise patients who take GLP-1 medications when preparing for endoscopic procedures, to have the best results. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 68, presented by TissueCypher from Castle Biosciences

In today's episode of the Innovation series, Dr. Parikh sits down with Mindy Mintz Mordecai, president and CEO of the Esophageal Cancer Action Network (ECAN). They discuss Mindy's journey, the origins of ECAN, and how it continues to support current and future patients with esophageal cancer. Today's episode was brought to you by Castle Biosciences, maker of TissueCypher, a test designed to predict the risk of esophageal cancer in patients with Barrett's esophagus. 

Get an exclusive look at the cutting-edge research on ocular melanoma, uveal melanoma, retinoblastoma, and more in this eye-opening video on eye cancer in 2024!Eye on Research 2024: Advancing Innovation in Cancer Research and TreatmentDescription:Welcome to the second annual "Eye on Research 2024" event! We are thrilled to be joined by a panel of esteemed doctors and researchers who are leading groundbreaking efforts in cancer research and treatment. Special thanks to all our guest doctors, including Dr. Correa and others, for their dedication to improving patient outcomes through innovation and cutting-edge science.Dr. Correa: Leading discussions on the latest advancements in cancer immunotherapy and the importance of personalized medicine in treating cancer patients.Additionally, we extend our gratitude to our generous sponsors, including Castle Biosciences, IDEAYA Biosciences, Aura Biosciences, TriSalus Life Sciences, Immunocore, Delcath, and Replimune, for making this event possible.Join us for this exciting session as we explore new frontiers in cancer research, including clinical trials, treatment strategies, and the potential for future breakthroughs. Thank you to everyone for being part of this incredible journey!

une in now to dive into Presley Jackson's incredible Polaroid project! Diagnosed at just 13, Presley has been unstoppable in sharing his journey these last few years, with the unwavering support of his amazing mom, Stephanie. His outlook in the face of #ocularmelanoma, his plaque treatment with Dr. Shields, and his transition into adulthood is nothing short of inspiring. Don't miss this video, and get ready for an exciting YouTube and Podcast channel launch later this week! A massive thank you to everyone who supports, organizes fundraisers, and participates in the Lookin' For A Cure For Ocular Melanoma 5k races! We can't achieve our goals without you, and we value every contribution! Please think about making a donation today to help ACIS continue to fund patient care, research, and educational programs like The Eye Believe Podcast. #ChildhoodCancerAwarenessMonth A special shoutout to Castle Biosciences, Inc. for sponsoring the podcast platforms!

Hope is on the Horizon with Dr. Shields! Please help us share this video to spread the hope in #ocularmelanoma Legendary Dr. Shields discloses the importance of early detection, advances in research, and helps you understand YOUR brand of #uvealmelanoma   Got questions? Share below and let us know so we can bring her back to bring you more of what you'd like to know!

Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique characteristics of prurigo nodularis (PN) and its clinical definition and explore how some of these characteristics are shared with atopic dermatitis, including underlying type 2 inflammation. They also discuss the need to raise awareness of this disease among both physicians and patients and educate that this is not a psychodermatological disorder. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr. Shawn Kwatra is an advisory board member/consultant for Abbvie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermavant, Galderma, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. Dr. Sonja Ständer was speaker and/or consultant and/or Investigator and/or has received research funding from AbbVie, Almirall, Beiersdorf, BMS, Clexio, Eli Lilly, FomF, Galderma, German Research Foundation (DFG), Integrity CE, Kiniksa, Leo Pharma, L'Oréal, MEDahead, Moroscience, NACCME, Novartis, Omnicuris, P.G. Unna Academy, Pfizer, Sanofi, TouchIME, UCB, Vifor, and WebMD. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400085- 1.0 - 08/2024 MAT-US-2408113 v1.0-P Expiration Date: 08/13/2026

Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the epidemiology, clinical presentation, and classification of atopic dermatitis of the hand and feet as well the as quantifying the multidimensional burden it has on patients' quality of life in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400314 - 1.0 - 06/2024  MAT-US-2405589 v1.0 - P Exp Date: 06/04/2026

Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the challenges associated with diagnosis of atopic dermatitis of the hands and feet and how disease severity can be assessed in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2402602- 1.0 - 05/2024 MAT-US-2405594 v1.0 - P Exp Date: 06/04/2026

Towny Robinson is the CEO of JayMac Pharmaceuticals and the inventor of EnLyte and EnBrace HR. He is a national expert on Methylation Biochemistry/Genetics and Psychiatric Disorders. Visit his website to learn more: www.enlyterx.com/about-enlyte www.enlyterx.com/about-enlyte Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc.  

Towny Robinson is the CEO of JayMac Pharmaceuticals and the inventor of EnLyte and EnBrace HR. He is a national expert on Methylation Biochemistry/Genetics and Psychiatric Disorders. Visit his website to learn more: www.enlyterx.com/about-enlyte www.enlyterx.com/about-enlyte Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc.  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025.Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerAdam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc.Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Co-Chair/PlannerShawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi.Co-Chair/PlannerPeter A. Lio, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt's Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Co-Chair/PlannerProfessor Dedee Murrell has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025.Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerAdam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc.Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Co-Chair/PlannerShawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi.Co-Chair/PlannerPeter A. Lio, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt's Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Co-Chair/PlannerProfessor Dedee Murrell has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025.Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerAdam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc.Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Co-Chair/PlannerShawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi.Co-Chair/PlannerPeter A. Lio, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt's Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Co-Chair/PlannerProfessor Dedee Murrell has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025.Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerAdam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc.Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Co-Chair/PlannerShawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi.Co-Chair/PlannerPeter A. Lio, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt's Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L'Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Co-Chair/PlannerProfessor Dedee Murrell has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Ocular Melanoma patients face a LOT in their diagnosis journey. Facing the fear of recurrence, the fear around scans, fear of dying - there's a lot to unpack. Join us to hear from Katie Wilson, a therapist and patient herself, who specifically studies resilience and the development of post traumatic growth. Katie Wilson is a therapist and an adult educator. She received her master's degree in counseling Psychology from Gonzaga in 2003. She has worked as a mental health clinician for almost 20 years specializing in trauma. Katie was a psychology instructor and spent several years teaching for North Idaho College. As a Ph.D. student at the University of Idaho, she has done extensive research on transformative learning, attachment theory, posttraumatic growth, and human flourishing in the adult organizational leadership and learning program. Katie has a history of volunteer work at Hospice of North Idaho and currently volunteers as an advocate for the Ocular Melanoma Foundation in which she provides education and mental health care for newly diagnosed cancer survivors. Katie is also a cancer survivor and is passionate about helping individuals live their best lives following trauma. Our mini seminar this year was brought to you by Castle Biosciences, as well as Aura Biosciences, Immunocore, IDEAYA Biosciences, Delcath Systems, and Trisalus Life Sciences. 

Ocular Melanoma is enough to justify extra support. Dr. Allison Dashow, a patient and psychologist, shares a summary of therapies patients may find supportive, emphasizing the skills that can be developed to reach a point of radical acceptance in your diagnosis. Dr. Allie Dashow is a clinical psychologist and has been seeing clients for psychotherapy and group therapy for the past 6 years. She specializes in the following therapy modalities: cognitive behavioral therapy, dialectical behavioral therapy, and acceptance and commitment therapy. Allie also specializes in eating disorders and body image difficulties. She has run multiple psychoeducational trainings for colleagues and early career therapists, workshops for students, and therapy groups relating to eating disorders, disordered eating, and body image challenges. In her spare time, she also spent 8 years as a senior administrator for Beating Eating Disorders, an online based platform with over 150,000 followers that aims to raise eating disorder awareness and provide support and resources to those in need. On the side, Allie also provides executive functioning coaching for people with ADHD. Our mini seminar this year was brought to you by Castle Biosciences, as well as Aura Biosciences, Immunocore, IDEAYA Biosciences, Delcath Systems, and Trisalus Life Sciences. 

Ocular Melanoma is a beast of a diagnosis. Fellow cancer survivor and patient Eve Bogdanove shares strategies for coping with your diagnosis and making meaning throughout the journey.  Eve N. Bogdanove has been a clinical social worker for 28 years. She is a psychodynamically trained with additional training in IFS, SE, EMDR, DBT and is a AASECT Certified Sex & Gender Therapist.  She has expertise in CPTSD and working with perpetrators who harm their intimate partners.    Our mini seminar this year was brought to you by Castle Biosciences, as well as Aura Biosciences, Immunocore, IDEAYA Biosciences, Delcath Systems, and Trisalus Life Sciences. 

Ocular Melanoma is a family disease. It doesn't just affect one person - having this diagnosis, the fear of the unknown can affect everyone from immediate family, friends, and more. Learning how to support each other with varying needs and boundaries amidst your diagnosis is worth the listen to this unique patient panel, led by patient and therapist, Carol McColl. Carol McColl has worked as a licensed professional counselor for 16 years, specializing in trauma recovery. She is also the author of The Single Mom's Devotional (Revell, 2009.) Carol lives in Dallas, TX, with her husband Angus, their adorable mini-goldendoodle Barney, and her 94-year old father, “Grampy." Carol's large step-family includes eight adult daughters, with various spouses and partners, and 10 grandchildren. Carol was diagnosed with OM in July 2018, and had plaque therapy in August 2018. In her free time, Carol enjoys coffee with friends, baking, crocheting, Bible study, serving at her church, travel, and quiet weekends at Holly Lake in East TX.  Our mini seminar this year was brought to you by Castle Biosciences, as well as Aura Biosciences, Immunocore, IDEAYA Biosciences, Delcath Systems, and Trisalus Life Sciences. 

Join A Cure in Sight, an ocular melanoma foundation, to bring you an Eye Believe Mini-Seminar, Eye on COOG, where we're joined by Dr. Harbour, Dr. Reichstein, Dr. Williams, and Dr. Correa to discuss the Collaborative Ocular Oncology Group, it's founding and history, the research this collaborative study has yielded, and where COOG hopes to take the ocular melanoma community in the future.  Topics covered: History of the COOG study Current Published Studies from COOG (COOG 1 and COOG 2) The Future of COOG Thank you to our Eye Believe 2023 sponsors who also helped sponsor this years mini eye believe online seminars. Castle Biosciences, Aura Biosciences, Immunocore, IDEAYA, Delcath Systems, and Trisalus Life Sciences.   ANNOUNCEMENTS: STEPS FOR SIGHT 2024 is still going strong--over $60k raised so far--an exciting feat! Be part of the world wide movement: www.charityfootprints.com/SFS2024   5K SITES ARE OPEN FOR REGISTRATION NEAR YOU! Start your team and bring your community to get involved! Highest record for registrations is 306! Who can top it!? Fundraisers have a record of $30K+ in Palo Alto–who can help beat that!?  March 24, 2024, Tampa, FL https://runsignup.com/Race/FL/Tampa/LookinForACureTampaFL March 30, 2024, Brooklyn, NY https://runsignup.com/Race/NY/Brooklyn/LookinForACureBrooklyn May 18, 2024, Raleigh, NC https://runsignup.com/Race/NC/Raleigh/LookinForACureRaleigh Head to our site to register for a 5K Lookin' for a Cure near you for the remainder of the year!! www.lookinforacure.org  COMING OCTOBER 2024: Eye Believe Survivorship Seminar in Scottsdale, Arizona - Join A Cure in Sight and Dr. Justin Moser from Honorhealth Research Institute for our upcoming survivorship seminar in the sunny state of Arizona! Details on registration coming soon! Subscribe to the newsletter to stay in the know Newsletter link Email contact@acureinsight.org for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or  Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via  PAYPAL OR VENMO or reach out directly to contact@acureinsight.org 

Patients with Barrett's Esophagus are at a higher risk to develop esophageal cancer, but it has always been challenging for physicians to determine which of their patients are at greatest risk. Dr. Michael Weinstein interviews Dr. Matthew Goldberg, who is medical director of Castle Biosciences about TissueCypher, a test to help gastroenterologists stratify risk for cancer in patients with Barrett's Esophagus. Join Dr. Weinstein and Dr. Goldberg to hear about how this innovative test can help gastroenterologists and pathologists better identify those patients who are most at risk and provide the appropriate care to help prevent them from developing esophageal cancer. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Original score by Hayden Margolis Gastro Broadcast, Episode 50

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Special Episode: Travel with us in this journey through the fascinating world of Medical Science Liaison (MSL), new career path for pharmacists! Get firsthand knowledge from the CEO of The MSL Society and how to break into the amazing career path. We are giving away a signed copy of the book "The Medical Science Liaison Career Guide: How to Break Into Your First Role". To the one lucky aspiring MSL, please share our podcast link, tag Becky, Behnaz, and Samuel Dyer and make sure to use the hashtag PGx4Rx to be entered into the contest. The winners will be announced in the first week of January 2024. Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc.

Special Episode: Travel with us in this journey through the fascinating world of Medical Science Liaison (MSL), new career path for pharmacists! Get firsthand knowledge from the CEO of The MSL Society and how to break into the amazing career path. We are giving away a signed copy of the book "The Medical Science Liaison Career Guide: How to Break Into Your First Role". To the one lucky aspiring MSL, please share our podcast link, tag Becky, Behnaz, and Samuel Dyer and make sure to use the hashtag PGx4Rx to be entered into the contest. The winners will be announced in the first week of January 2024.  Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc.  

Join A Cure in Sight to interview Dr. Jesse Berry for this episode chosen and sponsored by Castle Biosciences - the topic? Eye exams and early detection - does finding OM earlier REALLY make a difference? In what ways? Jesse L. Berry, MD is a board-certified ophthalmologist with subspecialty training in ocular oncology. She received her undergraduate and medical degree from Harvard University in Massachusetts. Following her ophthalmology residency at the University of Southern California, she was the Assistant Chief of Service at the Los Angeles County Medical Center. She completed a fellowship in Ocular Oncology at Children's Hospital Los Angeles. She currently serves as the Vice Chair for Academic Affairs for the Department of Surgery and Director of Ocular Oncology at the Vision Center, CHLA. Dr. Berry actively treats patients with retinoblastoma, uveal melanoma, intraocular and ocular surface tumors. She is active academically within the broader field of ophthalmology and ocular oncology. She is the Vice President for the International Society of Ocular Oncology and was the conference chair for the biennial meeting in Los Angeles in 2019. She is an active advocate for mentorship and opportunities for young ophthalmologists. As such, she is a member of the Young Ophthalmologist committee through the American Academy of Ophthalmology and co-leads the committee for young ophthalmic oncologists and pathologists (YOOPs). Dr. Berry is active within the Women in Ophthalmology organization and is the founder of WOO, Women in Ocular Oncology. As a physician-scientist, Dr. Berry studies outcomes for retinoblastoma, melanoma and other tumors. Her main interest is the development of the aqueous humor as a liquid biopsy for retinoblastoma and other intraocular disease. She was awarded a K08 from the National Cancer Institute of the National Institute of Health in 2018 to further study this. In 2019 she was promoted to Associate Professor of Ophthalmology, Clinical Scholar, a special distinction provided by USC. In 2021 she was awarded the prestigious USC Faculty Mentoring Award. She currently holds the USC Berle & Lucy Adams Chair in Cancer Research. ANNOUNCEMENTS: 5K SITES ARE OPEN FOR REGISTRATION NEAR YOU! Start your team and bring your community to get involved! Highest record for registrations is 306! Who can top it!? Fundraisers have a record of $30K+ in Palo Alto–who can help beat that!?  December 9, Dallas FTW TX https://runsignup.com/Race/TX/FortWorth/LookinForACureFortWorth December 10, Houston, TX https://runsignup.com/Race/TX/Houston/LookinForACureHouston January 20, 2024 Orlando FL https://runsignup.com/Race/FL/Orlando/LookinForACureTampa January 21, 2024, Miami FL https://runsignup.com/Race/FL/Miami/LookinForACureMiami Head to our site to register for a 5K Lookin' for a Cure near you for the remainder of the year!! www.lookinforacure.org Subscribe to the newsletter to stay in the know Newsletter link Email contact@acureinsight.org for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or  Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via  PAYPAL OR VENMO or reach out directly to contact@acureinsight.org 

Becky Winslow, BS, PharmD Host and Pharmacogenomics Medical Science Liaison; Behnaz Sarrami, MS, PharmD, Host and Pharmacogenomics Medical Science Liaison; Thierry Dervieux, PharmD, PhD, Chief Scientific Officer at Prometheus Laboratories Disclaimer: Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc. Becky Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of any other entity.   Transcription:  1 00:00:06,190 --> 00:00:19,620 You're listening to the Pharmacy podcast Network in a world where one size fits all medications dominate the pharmaceutical industry. 2 00:00:20,079 --> 00:00:24,750 Precision medicine brings a ray of hope for those seeking customized health care. 3 00:00:25,350 --> 00:00:32,830 Pharmacists have a unique opportunity to help people in need of specialized testing to ensure medications work as intended. 4 00:00:33,540 --> 00:00:44,680 Welcome to PGX for pharmacists where we unravel the wonders of precision medicine and its potential to revolutionize the way we approach pharmacy care. 5 00:00:45,169 --> 00:00:52,790 Get ready to uncover the secrets behind pharmacogenomics and how it's transforming lives one genome at a time. 6 00:00:52,799 --> 00:00:53,189 Hello, 7 00:00:53,200 --> 00:00:53,950 everyone. 8 00:00:54,159 --> 00:00:55,080 I'm your host, 9 00:00:55,090 --> 00:00:56,389 Doctor Becky Winslow. 10 00:00:56,409 --> 00:01:09,860 And you're listening to the PGX for Pharmacist podcast that we magazine recognized in 2021 as the ninth most listened to genetics podcasts in the world on the PGX for Pharmacist podcast. 11 00:01:09,870 --> 00:01:16,690 We explore all things pharmacogenomics related and our mission is to educate and advocate for PGX. 12 00:01:16,769 --> 00:01:23,849 We accomplish this mission through exclusive interviews with highly qualified and well experienced pharmacogenomics. 13 00:01:23,860 --> 00:01:29,720 Industry leaders such as today's special guest and my name is Baas Sami, 14 00:01:29,730 --> 00:01:32,739 the co-host of PGX for Pharms podcast, 15 00:01:32,750 --> 00:01:33,860 Pharmacogenomics, 16 00:01:33,870 --> 00:01:36,819 medical science liaison and a mentor to pharmacist. 17 00:01:36,889 --> 00:01:40,239 Connect with us on linkedin and let's get a conversation going. 18 00:01:40,269 --> 00:01:46,720 We want to hear from you and how you're impacting pharmacogenomic stakeholders and what you have learned throughout your journey. 19 00:01:48,510 --> 00:01:49,010 Ok. 20 00:01:49,019 --> 00:01:50,819 So without any further ado, 21 00:01:50,839 --> 00:01:54,769 I'm extremely pleased to introduce to our audience. 22 00:01:54,919 --> 00:01:56,059 Doctor Theory Devo, 23 00:01:57,239 --> 00:02:01,129 the Chief Scientific Officer at Prometheus Laboratories, 24 00:02:01,139 --> 00:02:08,139 and Perme Prometheus Laboratories is a reference clinical laboratory that's focused on the diagnosis, 25 00:02:08,149 --> 00:02:13,330 prognosis and monitoring of immune mediated inflammatory diseases. 26 00:02:13,970 --> 00:02:14,229 So, 27 00:02:14,240 --> 00:02:14,649 thank you, 28 00:02:14,660 --> 00:02:17,759 Doctor De for joining us on the podcast. 29 00:02:17,770 --> 00:02:18,589 Today. 30 00:02:18,600 --> 00:02:23,190 I'm excited to share your and Prometheus's story with our audience. 31 00:02:23,649 --> 00:02:25,630 Um in particular, 32 00:02:25,639 --> 00:02:45,369 I'm excited about you sharing your career journey as a farm D phd and Chief scientific officer and designer of the Predictor PK AD A which is a precision guided dosing test for the optimization of Humira Remicade and their bio cylinders. 33 00:02:46,119 --> 00:02:46,449 So, 34 00:02:46,460 --> 00:03:04,220 one of Bana's and my main goals for this episode of the PGX for Pharmacist podcast is to expand our audience's notion of what a PGX test looks like and to inspire them to think bigger than the traditional box PGX test. 35 00:03:04,229 --> 00:03:08,020 Most of them or most of you are uh familiar with. 36 00:03:09,020 --> 00:03:09,429 So, 37 00:03:09,440 --> 00:03:22,179 Doctor D uh I'd like to start the podcast by having our guests um introduce themselves and elaborate on how you are a pharmacogenomics expert. 38 00:03:23,619 --> 00:03:23,800 Yeah, 39 00:03:23,809 --> 00:03:24,250 thank you, 40 00:03:24,259 --> 00:03:25,759 Becky for having me. 41 00:03:25,770 --> 00:03:26,850 Uh uh Yes. 42 00:03:26,860 --> 00:03:27,289 So I am a, 43 00:03:27,300 --> 00:03:30,820 I am a pharmacist uh with uh a family who is a, 44 00:03:30,830 --> 00:03:33,039 a doctorate in pharmacokinetics. 45 00:03:33,539 --> 00:03:44,520 Uh I completed my studies in France and I came as a postdoc uh fellow uh to work in the United States about 20 years ago to work on the pharmacogenomic of anti cancer agents, 46 00:03:44,929 --> 00:03:49,160 uh primarily uh six Maturin as well as methotrexate. 47 00:03:49,169 --> 00:03:50,550 After my post doc, 48 00:03:50,770 --> 00:03:52,960 uh I moved uh in industry for promet. 49 00:03:53,490 --> 00:04:01,429 So I have a large experience in uh uh the implementation of pharmacogenetics testing in immune mediated inflammatory disease. 50 00:04:01,509 --> 00:04:12,550 Our lab Rome was the first uh clinical laboratory in the United States to offer the fin uh metyl transfer genotyping as well as the thin metabolites. 51 00:04:12,559 --> 00:04:13,029 So, 52 00:04:13,050 --> 00:04:21,989 uh uh of uh of 70 publications in the field and uh I'm very uh very excited to have uh to be on the postcard with you uh uh today. 53 00:04:23,660 --> 00:04:24,220 All right. 54 00:04:24,230 --> 00:04:27,359 So thank you for qualifying yourself as an expert. 55 00:04:27,369 --> 00:04:27,619 So, 56 00:04:27,630 --> 00:04:32,839 let's jump right in and delve into your current PGX work. 57 00:04:32,850 --> 00:04:33,279 So, 58 00:04:33,489 --> 00:04:36,540 if you'll tell us um a little about Prometheus, 59 00:04:36,549 --> 00:04:38,000 specifically, 60 00:04:38,010 --> 00:04:40,350 what is Prometheus's mission? 61 00:04:40,359 --> 00:04:43,799 And how are you guys going about accomplishing your mission? 62 00:04:44,760 --> 00:04:44,980 Yeah, 63 00:04:44,989 --> 00:04:45,700 sure. 64 00:04:45,709 --> 00:04:47,459 Uh So Promet is a, 65 00:04:47,470 --> 00:04:52,790 is a reference uh clinical laboratory based in Southern California in San Diego. 66 00:04:53,230 --> 00:04:56,809 Uh The company has been there for uh over 25 years. 67 00:04:56,820 --> 00:05:03,950 We are uh specialize in the differential diagnosis of autoimmune G I disease uh disorders, 68 00:05:04,059 --> 00:05:06,019 uh gastrointestinal disorder, 69 00:05:06,230 --> 00:05:08,619 uh and inflammatory bowel disease. 70 00:05:08,980 --> 00:05:10,299 And over the years, 71 00:05:10,309 --> 00:05:16,600 we have developed a portfolio of a differentiated solution to facilitate the diagnosis, 72 00:05:16,609 --> 00:05:17,470 the prognosis, 73 00:05:17,480 --> 00:05:18,429 the monitoring, 74 00:05:18,660 --> 00:05:21,910 as well as therapy selection with pharmacogenetics testing, 75 00:05:21,920 --> 00:05:24,730 which we are offering to our clinical laboratory. 76 00:05:24,829 --> 00:05:26,350 And most importantly, 77 00:05:26,410 --> 00:05:27,299 uh recently, 78 00:05:27,309 --> 00:05:35,660 we are uh uh developing some uh uh testing solution with the credit topic care test to optimize treatment to uh biologics. 79 00:05:36,470 --> 00:05:37,130 Ok. 80 00:05:37,140 --> 00:05:37,329 Well, 81 00:05:37,339 --> 00:05:37,450 that, 82 00:05:37,459 --> 00:05:38,049 that's great. 83 00:05:38,059 --> 00:05:46,100 Can you also tell us uh about the Prois Library of Precision Medicine Tests for inflammatory bowel disease for patients? 84 00:05:46,109 --> 00:05:49,230 how they benefit medication therapy management. 85 00:05:49,239 --> 00:05:56,429 Stakeholders across the IB DS patients journey from diagnosis to treatment to disease, 86 00:05:56,440 --> 00:06:02,049 monitoring through remission and how they differ from other lab tests for IBD and his treatments. 87 00:06:02,709 --> 00:06:03,209 Yes. 88 00:06:03,220 --> 00:06:03,369 So, 89 00:06:03,380 --> 00:06:04,399 so we uh our, 90 00:06:04,410 --> 00:06:10,100 our clinical laboratory offers some uh highly specialized test to facilitate the, 91 00:06:10,109 --> 00:06:16,779 the diagnostic of uh to facilitate the differential diagnosis of uh uh inflammatory bowel disease. 92 00:06:16,790 --> 00:06:22,359 So we are following uh testing solution with uh serological testing, 93 00:06:22,529 --> 00:06:23,799 for example, 94 00:06:23,809 --> 00:06:38,410 uh uh piana as as as well as uh macro microbial uh uh antibodies that are present uh uh in Crohn's disease as well as uh over uh auto uh auto antibodies that are present in er colitis. 95 00:06:39,339 --> 00:06:43,684 These are conditions that are uh uh somewhat difficult to treat. 96 00:06:43,704 --> 00:06:49,994 Uh And uh we are uh uh offering those tests to uh help uh gastroenterologist. 97 00:06:50,015 --> 00:06:51,114 Uh uh first of all, 98 00:06:51,125 --> 00:07:03,434 to establish a differential diagnosis of IBD as compared to other uh condition typically uh uh irritable bowel syndrome as well as over gastrointestinal disorder. 99 00:07:03,445 --> 00:07:05,635 When the diagnostic is established, 100 00:07:05,910 --> 00:07:31,839 uh we offer uh testing to uh establish a prognosis where we're gonna in inform the clinician that the patient has a more aggressive uh disease that will require more aggressive treatment where uh we can uh provide the testing solution to initiate uh uh the most appropriate therapy for uh for the patient uh with uh a testing where we are uh basically uh you know, 101 00:07:31,850 --> 00:07:36,559 establish de determining some genotyping with the fit transferal genotyping. 102 00:07:36,570 --> 00:07:37,279 For example, 103 00:07:37,290 --> 00:07:40,250 where we can uh indicate that the patient is, 104 00:07:40,260 --> 00:07:45,079 is likely uh to present with a side effect to those medication. 105 00:07:45,399 --> 00:07:46,170 And once you know, 106 00:07:46,179 --> 00:07:47,799 the the treatment is initiative, 107 00:07:47,809 --> 00:08:16,089 we have a portfolio of solution uh to facilitate the monitoring of the disease of the inflammatory bowel disease as well as the dosing optimization with uh uh the answer test which uh measure blood level uh for uh uh monoclonal antibodies that are indicated in the treatment of IB start with starting with Infliximab Adalimumab as well as uh Tein and vidal. 108 00:08:16,980 --> 00:08:24,040 So we have a comprehensive portfolio to uh to surround the clinician with uh a variety of testing solution. 109 00:08:24,049 --> 00:08:30,250 With our goal being to improve the uh the outcome uh of patients with uh with diabetes. 110 00:08:30,260 --> 00:08:34,520 And I think that the pharmacist has a very important role to play from that perspective. 111 00:08:35,179 --> 00:08:36,039 So theory, 112 00:08:36,049 --> 00:08:40,239 could you elaborate for us more on the predictor test? 113 00:08:40,249 --> 00:08:42,758 Um especially since you designed that test, 114 00:08:42,768 --> 00:08:44,218 we'd really like to know, 115 00:08:44,489 --> 00:08:45,039 um you know, 116 00:08:45,049 --> 00:08:49,638 what did that take and what role does it play in your suite of testing? 117 00:08:51,049 --> 00:08:51,270 Yeah. 118 00:08:51,280 --> 00:08:51,890 Sure. 119 00:08:51,900 --> 00:08:52,510 So the, 120 00:08:52,520 --> 00:08:52,570 the, 121 00:08:52,580 --> 00:08:52,989 the, 122 00:08:53,000 --> 00:08:53,229 the, 123 00:08:53,239 --> 00:08:59,960 the predictor test is uh uh is uh is utilized when the patient is receiving treatment. 124 00:09:00,280 --> 00:09:18,190 It's been speci specifically designed to optimize uh biological uh uh disease modifiers such as Infliximab adalimumab that are co therapies in the treatment of inflammatory bowel disease as well as other immune uh mediated inflammatory. 125 00:09:18,200 --> 00:09:21,549 This is what the test does is to you connect the blood specimen, 126 00:09:22,229 --> 00:09:23,049 uh you know, 127 00:09:23,059 --> 00:09:24,750 with dosing information. 128 00:09:25,039 --> 00:09:41,989 And what we do is to uh uh provide guidance uh to clinician with uh respect of the best dose to give in order to achieve the best the level which is the most consistent with uh uh the disease control that needs to be achieved for the patient. 129 00:09:42,169 --> 00:09:43,729 Typically a vast majority, 130 00:09:43,739 --> 00:09:46,159 about two third of a third to two third, 131 00:09:46,169 --> 00:09:54,669 a third of patient uh tend to be uh uh unresponsive uh to this uh very expensive medication. 132 00:09:54,989 --> 00:09:57,960 Uh Not because they don't have the uh you know, 133 00:09:57,969 --> 00:09:59,289 typically because they have a, 134 00:09:59,299 --> 00:09:59,590 you know, 135 00:09:59,599 --> 00:10:05,599 pharmacokinetic uh suboptimal pharmacokinetic uh that makes them uh you know, 136 00:10:05,609 --> 00:10:09,440 unresponsive because uh not enough drug has been given. 137 00:10:09,450 --> 00:10:18,469 So what we do with a predictor test is to basically estimate the pa the pharmacokinetic uh parameter for the patient. 138 00:10:18,750 --> 00:10:24,729 And from then uh re report the best dose uh to give in order to achieve the, 139 00:10:24,760 --> 00:10:31,570 the level which is consistent with the uh the most uh uh effective disease control to be achieved for the patient. 140 00:10:32,169 --> 00:10:33,059 So we are offering, 141 00:10:33,070 --> 00:10:38,049 we have developed a test for the Infliximab as well as Adalimumab which is Humira, 142 00:10:38,909 --> 00:10:41,309 but these are antimony causes factor. 143 00:10:41,460 --> 00:10:49,549 And we are also developing the test for vidur as well as uh is that are widely used also in the treatment of, 144 00:10:49,559 --> 00:10:51,969 of uh inflammatory bubble disease. 145 00:10:51,979 --> 00:10:52,669 Wow, 146 00:10:52,679 --> 00:10:55,450 uh for MET is a suite of tests. 147 00:10:55,460 --> 00:11:00,940 Goes well beyond um the PGX testing that our audience is most familiar with, 148 00:11:01,299 --> 00:11:08,679 uh which typically only includes snips for cyp genes and some pharmacodynamic genes. 149 00:11:08,690 --> 00:11:31,424 This is really exciting um genes and biomarkers related to immunology are not commonly found in what I call the box PGX tests such as those uh made by large uh laboratory manufacturing companies um where the panel has a set number of genes and uh you know, 150 00:11:31,434 --> 00:11:36,054 it was developed by a larger laboratory for maybe smaller laboratories use. 151 00:11:36,729 --> 00:11:39,010 So my understanding, 152 00:11:39,020 --> 00:11:53,729 having talked with you extensively theory is that immunology has fewer PGX test available because it's actually more difficult say than oncology to research and develop tests. 153 00:11:53,739 --> 00:11:54,119 So, 154 00:11:54,130 --> 00:12:00,729 could you elaborate for our audience on the difficulties that are associated with immunology, 155 00:12:00,739 --> 00:12:05,830 research and developing tests uh for immunology versus say oncology? 156 00:12:06,330 --> 00:12:06,530 Yeah, 157 00:12:06,539 --> 00:12:07,049 sure. 158 00:12:07,059 --> 00:12:09,969 So in uh in immunology, 159 00:12:09,979 --> 00:12:11,590 as compared to oncology, 160 00:12:11,599 --> 00:12:17,169 there is no such a thing such as a somatic mutation where for example, 161 00:12:17,179 --> 00:12:18,429 you're gonna have a behalf, 162 00:12:18,440 --> 00:12:18,659 you know, 163 00:12:18,669 --> 00:12:20,349 that indicates that the patient, 164 00:12:20,679 --> 00:12:20,919 you know, 165 00:12:20,929 --> 00:12:25,239 is likely to benefit or not from some treatment in immunology. 166 00:12:25,250 --> 00:12:26,750 This is far more complicated, 167 00:12:26,760 --> 00:12:28,830 complicated for the reason, 168 00:12:29,239 --> 00:12:31,020 starting with uh the fact that, 169 00:12:31,030 --> 00:12:31,179 you know, 170 00:12:31,190 --> 00:12:36,219 the response to this uh medication uh are multifactorial. 171 00:12:36,260 --> 00:12:37,820 And the fact that uh you know, 172 00:12:37,830 --> 00:12:39,380 the mutation that uh the, 173 00:12:39,390 --> 00:12:39,619 the, 174 00:12:39,630 --> 00:12:45,190 the single nucleotide polymorphism in the GM line which uh uh you know, 175 00:12:45,200 --> 00:12:52,429 can potentially associate with uh with outcome uh uh uh uh a lo in advance, 176 00:12:52,440 --> 00:12:58,359 meaning that uh they're gonna have a weak association uh with a response to those medications. 177 00:12:58,369 --> 00:13:09,609 So there is a necessity in immunology to combine multiple genetic polymorphism together in order to achieve uh some uh performances characteristics that will make uh you know, 178 00:13:09,619 --> 00:13:09,859 the, 179 00:13:09,869 --> 00:13:10,380 the, 180 00:13:10,390 --> 00:13:10,520 the, 181 00:13:10,530 --> 00:13:13,219 the clinician uh you know, 182 00:13:13,419 --> 00:13:15,619 uh order the test and most importantly, 183 00:13:15,630 --> 00:13:15,840 the, 184 00:13:15,849 --> 00:13:16,179 the, 185 00:13:16,190 --> 00:13:17,739 the payer to pay for the test. 186 00:13:17,750 --> 00:13:20,469 So this field has been uh you know, 187 00:13:20,479 --> 00:13:20,679 is, 188 00:13:20,690 --> 00:13:21,705 is moving for, 189 00:13:21,715 --> 00:13:21,994 you know, 190 00:13:22,005 --> 00:13:24,575 there are some tests that are being developed right now. 191 00:13:24,924 --> 00:13:39,034 But the biggest challenge is to be able to achieve again the the threshold of uh of performance that makes the test is variable enough uh to be uh again ordered by the clinician and the utilize uh to the benefit of the patient. 192 00:13:39,659 --> 00:13:41,200 I couldn't agree with you more. 193 00:13:41,210 --> 00:13:53,489 Um I've worked on the payer side or market access side of pharmacogenomics and even uh with a box test for which there's um a lot of research data available, 194 00:13:53,500 --> 00:13:55,119 even with those, 195 00:13:55,130 --> 00:13:59,760 it's sometimes difficult uh to get payers um to see the value. 196 00:13:59,770 --> 00:14:01,640 So I absolutely agree with you. 197 00:14:01,940 --> 00:14:03,679 Um The fact that you guys are, 198 00:14:03,690 --> 00:14:11,789 are uh investing in producing the data necessary says a lot about your laboratory. 199 00:14:11,979 --> 00:14:12,559 Um you know, 200 00:14:12,570 --> 00:14:15,380 and how committed you are to this testing and, 201 00:14:15,390 --> 00:14:17,320 and how you believe in the testing. 202 00:14:18,039 --> 00:14:23,640 So I just want to make sure that our audience recognizes that, 203 00:14:24,359 --> 00:14:24,619 you know, 204 00:14:24,630 --> 00:14:31,820 Prometheus doesn't simply provide tests to determine if drugs for IBD will be effective and safe. 205 00:14:32,190 --> 00:14:36,900 Um And maybe what the dose of the drug should be for the patient, 206 00:14:36,909 --> 00:14:40,219 but you have that whole suite of tests. 207 00:14:40,229 --> 00:14:47,380 Um the diagnostic test for the differential diagnosis all the way through remission. 208 00:14:48,030 --> 00:14:53,390 So can you elaborate you elaborated on it some in the previous question? 209 00:14:53,400 --> 00:15:01,229 But um can you tell us the difference between how you had to actually develop the test? 210 00:15:01,520 --> 00:15:02,530 Um You didn't, 211 00:15:02,539 --> 00:15:03,059 in other words, 212 00:15:03,070 --> 00:15:10,659 purchase a test from another manufacturer with the biomarkers that you include in your testing. 213 00:15:10,669 --> 00:15:16,830 Can you elaborate on how much more difficult it is to to develop a test from scratch? 214 00:15:18,169 --> 00:15:18,320 Yeah, 215 00:15:18,330 --> 00:15:18,659 sure. 216 00:15:18,669 --> 00:15:18,809 I mean, 217 00:15:18,820 --> 00:15:22,070 this is this is challenging for multiple and first of all, 218 00:15:22,080 --> 00:15:23,130 you need to have the, 219 00:15:23,419 --> 00:15:27,450 you need to have a clinical data set available with specimen available. 220 00:15:27,460 --> 00:15:28,159 Uh you know, 221 00:15:28,169 --> 00:15:28,780 in front, 222 00:15:28,859 --> 00:15:29,770 obviously, 223 00:15:29,859 --> 00:15:30,890 available. 224 00:15:31,200 --> 00:15:35,890 Uh So we are leveraging a pro meters a large bi bank of specimen. 225 00:15:36,299 --> 00:15:37,190 Uh as I said, 226 00:15:37,200 --> 00:15:39,719 Prometheus has been founded 25 years ago. 227 00:15:39,729 --> 00:15:40,599 So over the, 228 00:15:40,760 --> 00:15:41,919 the past two decades, 229 00:15:41,929 --> 00:15:54,849 we have been able to assemble a large uh substrate of data and specimen which we are uh uh using to uh uh establish our proof of concept if you will. 230 00:15:54,859 --> 00:16:07,559 And then when we have uh identify some genetic polymorphism that are uh adequately uh associated with uh uh disease outcome and disease progression as well as uh toxicity. 231 00:16:07,969 --> 00:16:11,469 Then we are entering validation phase where we are uh you know, 232 00:16:11,570 --> 00:16:14,789 using validation cohorts where we are again, 233 00:16:14,969 --> 00:16:22,630 combining multiple modalities together uh patient demographic as well as genetic marker together with theological marker. 234 00:16:22,640 --> 00:16:23,190 Actually, 235 00:16:23,500 --> 00:16:27,419 to come up with some Multivariate models that are uh again, 236 00:16:27,429 --> 00:16:39,250 bringing the performances characteristics of the pharmacogenomic test or its combination with our marker to the level where it's supposed to be in the first place to meet uh uh payer. 237 00:16:39,650 --> 00:16:41,190 And uh obviously, 238 00:16:41,200 --> 00:16:41,760 again, 239 00:16:41,770 --> 00:16:45,320 the patient uh to the benefit of the patient and to, 240 00:16:45,330 --> 00:16:46,619 to improve its outcome, 241 00:16:46,739 --> 00:16:47,429 the outcome. 242 00:16:48,340 --> 00:16:53,380 I think what you're describing really is the future of pharmacogenomics. 243 00:16:53,390 --> 00:16:54,599 Um In other words, 244 00:16:54,609 --> 00:17:03,419 not singing out pharmacogenomics as you know the end all and be all in the treatment paradigm. 245 00:17:03,559 --> 00:17:08,040 But using a PGX test in combination with, 246 00:17:08,050 --> 00:17:09,069 like you mentioned, 247 00:17:09,250 --> 00:17:11,160 other serological tests, 248 00:17:11,170 --> 00:17:12,959 maybe other genetic tests. 249 00:17:13,290 --> 00:17:14,890 Um But you know, 250 00:17:14,900 --> 00:17:25,869 I think what we want our audience to really wrap their heads around is that PGX is just a piece of that larger puzzle um from diagnosis to treatment to, 251 00:17:25,880 --> 00:17:26,910 to remission. 252 00:17:27,239 --> 00:17:29,880 So I think you guys are absolutely, 253 00:17:29,890 --> 00:17:31,579 you're already in the future. 254 00:17:31,589 --> 00:17:32,849 In other words, 255 00:17:32,859 --> 00:17:33,130 you know, 256 00:17:33,140 --> 00:17:39,689 you're already providing all these different uh tests um like you mentioned to, 257 00:17:39,699 --> 00:17:44,310 to facilitate from diagnosis to remission to remission. 258 00:17:44,660 --> 00:17:45,520 That's correct. 259 00:17:45,530 --> 00:17:45,829 Yeah. 260 00:17:46,349 --> 00:17:55,089 So um you've given us so much great information about uh the tests that that you guys offer. 261 00:17:55,329 --> 00:18:02,060 Can you explain to our audience um your newest test? 262 00:18:02,069 --> 00:18:03,859 Uh the responder test. 263 00:18:04,150 --> 00:18:12,979 And um what role it will play in the paradigm from the diagnosis of IBD to remission? 264 00:18:14,050 --> 00:18:14,260 Yeah, 265 00:18:14,270 --> 00:18:14,760 sure. 266 00:18:14,770 --> 00:18:15,569 So we, 267 00:18:15,579 --> 00:18:18,069 we are doing things a little bit different than other. 268 00:18:18,079 --> 00:18:19,489 We do believe that uh you know, 269 00:18:19,500 --> 00:18:21,449 the it has to be simple. 270 00:18:21,459 --> 00:18:24,189 Uh uh We can obviously construct some very, 271 00:18:24,199 --> 00:18:33,530 very complex algorithm and there are some tests that do that with a very sophisticated machine learning based tools that are available using neural networks, 272 00:18:33,540 --> 00:18:33,729 you know, 273 00:18:33,739 --> 00:18:34,790 those sorts of things. 274 00:18:34,800 --> 00:18:39,729 But we have taken on a different approach where with the responder test, 275 00:18:39,739 --> 00:18:40,329 we are basically, 276 00:18:40,339 --> 00:18:45,160 we are taking an approach which is very simple to address the first and foremost. 277 00:18:45,170 --> 00:18:53,020 Most important aspect of responding uh predicting response to uh to medication is the pharmacokinetics. 278 00:18:53,280 --> 00:19:03,250 Uh You cannot be responding to a drug if the drug is not given and you obviously cannot respond to a drug if the drug is not metabolized adequately. 279 00:19:03,359 --> 00:19:06,349 And this is what we are doing with the responder test. 280 00:19:06,579 --> 00:19:09,010 We are addressing some uh uh you know, 281 00:19:09,020 --> 00:19:11,630 fundamental issues with those uh biologist, 282 00:19:11,640 --> 00:19:12,410 for example, 283 00:19:12,660 --> 00:19:15,170 uh the anti tumor necrosis factors. 284 00:19:15,180 --> 00:19:15,650 So, 285 00:19:15,750 --> 00:19:19,199 such as uh Infliximab and Adalimumab, 286 00:19:19,209 --> 00:19:23,050 it is well known uh that uh uh those drugs, 287 00:19:23,060 --> 00:19:25,689 first of all are prone to immunization. 288 00:19:25,989 --> 00:19:36,949 Uh Meaning that uh uh the drug itself uh is recognized by the immune system uh and digested by the antigen presenting cells. 289 00:19:36,959 --> 00:19:42,209 If you will uh where you gonna have uh uh an immune uh uh response, 290 00:19:42,380 --> 00:19:56,979 uh mounted a cancer drug to produce uh immunogen that will severely impact its pharmacokinetics where the labels will be inadequate to produce uh the desired uh anti-inflammatory effects. 291 00:19:56,989 --> 00:19:57,150 So, 292 00:19:57,160 --> 00:19:58,890 we are with the risk conductors, 293 00:19:58,900 --> 00:20:01,040 we are combining two things together. 294 00:20:01,189 --> 00:20:07,959 First of all is the genetic test itself which uh predicts the risk of immun immunization. 295 00:20:07,969 --> 00:20:18,010 The name of the test is on HL A uh DQ A 105 ali uh that uh uh promotes the presentation of the, 296 00:20:18,020 --> 00:20:19,130 of the, 297 00:20:19,140 --> 00:20:19,910 of Infliximab, 298 00:20:20,010 --> 00:20:20,750 for example, 299 00:20:20,760 --> 00:20:32,130 to the T cell repertoire in order to uh promote the Ronon expansion and the formation of the anti antibodies together with uh another dimension which is the clearance, 300 00:20:32,140 --> 00:20:33,670 which is as important. 301 00:20:33,949 --> 00:20:36,209 Uh One of the key issue is the, 302 00:20:36,219 --> 00:20:36,770 the, 303 00:20:36,780 --> 00:20:41,239 the monoclonal antibodies and uh such as Infliximab or Adalimumab. 304 00:20:41,329 --> 00:20:42,280 But in fact, 305 00:20:42,290 --> 00:20:45,890 a neon antibodies that those drugs are uh you know, 306 00:20:45,900 --> 00:20:49,010 cleared and consumed uh from the, 307 00:20:49,020 --> 00:20:50,949 from the central compartment if you will, 308 00:20:50,959 --> 00:20:54,520 since we are doing a little bit of uh uh pharmacokinetics here. 309 00:20:54,530 --> 00:20:56,020 And uh uh you know, 310 00:20:56,030 --> 00:21:06,670 if the patient present who is uh a high degree of inflammatory burden is gonna have uh the patient will have a high clearance and that's gonna worsen uh in the, 311 00:21:06,680 --> 00:21:13,939 in the presence again of the HL AD Q A 105 genetic marker that uh associate with uh immunization. 312 00:21:13,949 --> 00:21:16,859 So I but this is a combination of both, 313 00:21:17,199 --> 00:21:19,359 these are the predictive factors of pharmacokinetic, 314 00:21:20,359 --> 00:21:38,209 which we combine together where the patient presenting with a risk of immunization as well as accelerated clearance due to the fact that the patient has high inflammation or due to the fact that they are so intrinsic pharmacokinetic properties that makes that the patient, 315 00:21:38,219 --> 00:21:38,300 you know, 316 00:21:38,310 --> 00:21:39,479 will clear the drug very, 317 00:21:39,489 --> 00:21:40,260 very fast. 318 00:21:40,560 --> 00:21:41,670 For example, 319 00:21:41,680 --> 00:21:46,819 due to the inefficient uh recirculation of the drug itself with the new, 320 00:21:46,869 --> 00:21:46,930 the, 321 00:21:46,939 --> 00:21:50,599 the the in the reticular on the system. 322 00:21:50,920 --> 00:21:51,619 Together, 323 00:21:51,630 --> 00:22:02,109 those patients presenting with uh uh together these uh poor prognostic factor of pharmacokinetic origin will tend to be severely underdose, 324 00:22:02,380 --> 00:22:06,719 will not be responding to the drug uh adequately as and they, 325 00:22:06,729 --> 00:22:10,719 and they probably should in the first place if you are able to address uh you know, 326 00:22:10,729 --> 00:22:12,270 the the the exposure. 327 00:22:12,439 --> 00:22:14,079 So what we do with this test, 328 00:22:14,089 --> 00:22:21,640 we will be able to inform uh the clinic that the patient is at risk of achieving, 329 00:22:21,650 --> 00:22:30,829 of achieving suboptimal pharmacokinetics and therefore being able to adjust the dose uh uh to start with more adequately. 330 00:22:30,839 --> 00:22:38,650 So that the the the proper uh exposure is achieved uh during induction to again to, 331 00:22:38,660 --> 00:22:39,040 to, 332 00:22:39,050 --> 00:22:39,380 to, 333 00:22:39,390 --> 00:22:40,890 to achieve a better outcome. 334 00:22:41,040 --> 00:22:47,270 And I think the pharmacist will have a very important role to play here in terms of absolutely, 335 00:22:47,280 --> 00:22:51,239 that information is priceless in the management of these medications. 336 00:22:51,250 --> 00:22:54,930 So thanks for elaborating on that. 337 00:22:56,010 --> 00:22:59,040 And if I may add in our previous conversation, 338 00:22:59,050 --> 00:23:00,810 uh before the recording of podcast, 339 00:23:00,819 --> 00:23:08,869 we had discussed um you guys' robust platform for collaborating with payers to obtain market access and reimbursements for the test. 340 00:23:09,109 --> 00:23:14,109 But without stealing the Thunder from uh Prometheus market access and reimbursement team, 341 00:23:14,199 --> 00:23:22,619 can you please uh briefly detail how Prometheus has proactively worked with payers to solve the problem. 342 00:23:22,920 --> 00:23:27,349 Um the population health problem by building the evidence payers want, 343 00:23:27,359 --> 00:23:41,170 want to see um about your test before you go to the market and then build the test and then hope the payers will see the value and the result and then that will improve the market access and reimbursement for your um precision medicine test. 344 00:23:42,160 --> 00:23:42,339 Yeah. 345 00:23:42,349 --> 00:23:43,180 So briefly I can, 346 00:23:43,189 --> 00:23:43,579 I'm, 347 00:23:43,589 --> 00:23:46,619 I'm probably not the right person to answer that question. 348 00:23:46,630 --> 00:23:47,369 We have a very, 349 00:23:47,380 --> 00:23:52,400 very efficient market access group uh uh pro meters that does a splendid job. 350 00:23:52,410 --> 00:23:59,780 But uh uh uh what I can tell you that we have an evidence uh uh development plan in place where we, 351 00:23:59,790 --> 00:24:14,000 we are establishing the clinical utility of our testing solution by demonstrating uh the payer value uh with respect of uh patient management and uh uh and the, 352 00:24:14,010 --> 00:24:16,630 and the impact of our technology on the, 353 00:24:16,640 --> 00:24:18,119 on physician behavior. 354 00:24:18,430 --> 00:24:21,319 Uh We have uh uh already uh you know, 355 00:24:21,329 --> 00:24:25,160 commercialized uh two of those tests for which we have initiated, 356 00:24:25,170 --> 00:24:29,040 initiated the Power studies uh that uh uh you know, 357 00:24:29,050 --> 00:24:32,000 already provide uh you know, 358 00:24:32,104 --> 00:24:34,484 differentiated and the value to, 359 00:24:34,494 --> 00:24:35,915 to the payer where we are, 360 00:24:35,925 --> 00:24:36,025 the, 361 00:24:36,035 --> 00:24:46,005 the clinicians are basically using our technology to make treatment decision uh as well as uh some prospective clinicality study which we are initiating, 362 00:24:46,145 --> 00:24:47,555 initiating to. 363 00:24:47,564 --> 00:24:48,574 Um uh again, 364 00:24:48,584 --> 00:24:49,425 demonstrate the, 365 00:24:49,435 --> 00:24:49,915 the, 366 00:24:49,925 --> 00:24:50,244 the, 367 00:24:50,255 --> 00:24:53,594 the payer value you uh uh we can certainly follow up with, 368 00:24:53,604 --> 00:24:58,755 uh you can certainly follow up with our market access group uh uh as appropriate there. 369 00:24:58,765 --> 00:25:00,765 Uh They can fill you with more information. 370 00:25:01,349 --> 00:25:01,589 No, 371 00:25:01,599 --> 00:25:02,520 that totally makes sense. 372 00:25:02,530 --> 00:25:03,310 That totally makes sense. 373 00:25:03,319 --> 00:25:10,890 But um we're excited that you're also farm d So how did you get to this role of outside the box path? 374 00:25:10,900 --> 00:25:11,550 There? 375 00:25:11,640 --> 00:25:17,530 There may be a pharmacist student or pharmacist wanting to switch or transition into a role such as yours, 376 00:25:17,540 --> 00:25:19,609 which is a Chief Scientific Officer. 377 00:25:19,619 --> 00:25:20,609 I want to learn more. 378 00:25:20,619 --> 00:25:23,920 So how would you um can you talk a little bit about that? 379 00:25:24,560 --> 00:25:24,780 Well, 380 00:25:24,790 --> 00:25:26,270 we are clinical laboratories. 381 00:25:26,280 --> 00:25:29,400 So in order to uh uh to be in my role, 382 00:25:29,410 --> 00:25:34,020 you need to have uh uh you need to have expertise in clinical laboratory science. 383 00:25:34,030 --> 00:25:36,140 So for the students is basically, 384 00:25:36,150 --> 00:25:36,300 you know, 385 00:25:36,310 --> 00:25:40,770 to do the family degree and then complete the family degree with uh a doctorate, 386 00:25:40,780 --> 00:25:40,930 you know, 387 00:25:40,939 --> 00:25:44,260 which is uh focus on clinical laboratory science. 388 00:25:44,270 --> 00:25:46,079 So you can achieve uh uh you know, 389 00:25:46,089 --> 00:25:47,640 the all the elements you need to be, 390 00:25:47,650 --> 00:25:48,219 for example, 391 00:25:48,229 --> 00:25:53,189 board certified uh as uh as as medical laboratory director. 392 00:25:53,199 --> 00:25:55,160 So you can uh uh so, 393 00:25:55,170 --> 00:25:55,589 uh yeah, 394 00:25:55,599 --> 00:25:56,030 this is, 395 00:25:56,040 --> 00:25:56,400 this is, 396 00:25:56,410 --> 00:25:57,209 this is uh you know, 397 00:25:57,219 --> 00:25:59,160 a great opportunity I think for pharmacies, 398 00:25:59,170 --> 00:26:10,800 there is an absolute need to uh have the clinical pharmacist provide uh uh drug information to healthcare professional as well as uh assist patient with the monitoring of their disease, 399 00:26:10,810 --> 00:26:15,229 the effectiveness of the therapy and um and uh you know, 400 00:26:15,239 --> 00:26:16,060 monitoring the, 401 00:26:16,069 --> 00:26:20,969 the side effect and the toxicity from uh from those uh those medication. 402 00:26:24,650 --> 00:26:24,959 Well, 403 00:26:24,969 --> 00:26:32,119 the I know our audience is going to have uh additional questions for you. 404 00:26:32,130 --> 00:26:32,540 I mean, 405 00:26:32,989 --> 00:26:35,609 you've provided them with so much great information, 406 00:26:35,619 --> 00:26:44,959 but it's only the beginning of what they could possibly learn um about um the testing that you do for IBD and, 407 00:26:44,969 --> 00:26:46,729 and even your career path. 408 00:26:47,050 --> 00:26:47,530 So, 409 00:26:47,540 --> 00:26:49,300 if you wouldn't mind telling us, 410 00:26:49,310 --> 00:26:51,359 um because we have to wrap up, 411 00:26:51,369 --> 00:26:52,670 unfortunately, 412 00:26:53,150 --> 00:26:55,810 this episode of the podcast, 413 00:26:55,819 --> 00:27:00,250 uh could you tell us how our audience members might be able to contact you directly. 414 00:27:01,260 --> 00:27:01,449 Yeah, 415 00:27:01,459 --> 00:27:07,079 I can be contacted on my uh on my email at TT W at como slab dot com. 416 00:27:07,949 --> 00:27:08,810 All right. 417 00:27:09,069 --> 00:27:09,300 Well, 418 00:27:09,310 --> 00:27:14,290 thank you again so much uh for joining us on this episode. 419 00:27:14,300 --> 00:27:15,290 We really, 420 00:27:15,300 --> 00:27:29,530 really hope that our listeners um ideas of not only what PGX can be but how PGX can be utilized in a comprehensive testing suite. 421 00:27:29,709 --> 00:27:35,670 We really hope that our a our audience will um listen in and learn this information. 422 00:27:36,280 --> 00:27:37,869 Um And to our audience, 423 00:27:37,880 --> 00:27:39,439 thank you for tuning in. 424 00:27:39,449 --> 00:27:42,619 We really hope that you've learned from this episode. 425 00:27:43,130 --> 00:27:46,339 Uh We do a whole lot of PG Xing here on this podcast. 426 00:27:46,349 --> 00:27:48,380 We talk about PGX Science, 427 00:27:48,390 --> 00:27:52,030 clinical application and the business of PGX. 428 00:27:52,260 --> 00:27:54,880 So we'd love to hear about from you. 429 00:27:55,099 --> 00:27:56,479 I love to hear from you. 430 00:27:56,489 --> 00:27:58,439 Um What can we teach you? 431 00:27:58,449 --> 00:28:00,920 What more can we teach you through our podcast? 432 00:28:00,930 --> 00:28:12,349 So please drop us a message on linkedin and let us know and please share this link to this podcast link episode with everyone so they can tune in and listen to the PGX for promises podcast. 433 00:28:12,520 --> 00:28:15,369 Leave us a review on Apple podcast or Spotify. 434 00:28:15,459 --> 00:28:18,130 And you can also visit us on PGX four, 435 00:28:18,140 --> 00:28:22,989 the number four Rx dot com to listen to all our other episodes. 436 00:28:23,000 --> 00:28:23,079 Well, 437 00:28:23,089 --> 00:28:23,790 thank you. 438 00:28:24,199 --> 00:28:28,750 Thanks for your interest in PGX and for spending some time with us. 439 00:28:28,760 --> 00:28:35,670 Please share this podcast and leave us a review on Apple podcasts or Spotify for all of our episodes. 440 00:28:35,680 --> 00:28:39,390 Please visit PGX for Rx dot com. 441 00:28:39,569 --> 00:28:43,380 That's PGX for Rx dot com.  

Welcome to this year's Eye Believe 2023 Survivorship Seminar recording series. A discussion on Integrative Medicine and Ocular Melanoma with Blake Langley. Dr. Blake Langley is a licensed naturopathic physician and acupuncturist studying the impact of acupuncture therapies on quality of life and clinical outcomes in patients receiving active treatment for various cancers. As a Staff Scientist at the Fred Hutchinson Cancer Center, Dr. Langley works administers acupuncture for multiple clinical trials and serves as the principal investigator for an NCCIH-funded clinical trial assessing the use of ear seeds in outpatient settings. Dr. Langley is passionate about conducting research that supports increased patient access to integrative therapies nationwide. Learn more at https://www.fredhutch.org/en/patient-care/services/integrative-medicine.html email Dr. Langley blangley@fredhutch.org    Our seminar this year was brought to you by Castle Biosciences and co-hosted by University of Washington Eye Institute, and Fred Hutch Cancer Center, and the Ocular Melanoma Foundation. This year's sponsors include Aura Biosciences, Immunocore, IDEAYA, Delcath Systems, Trisalus Life Sciences, North West Eye Design, and Replimune. Special thanks to our hosting doctor, Dr. Stacey, and all speakers and participants who made this possible.   ANNOUNCEMENTS: 5K SITES ARE OPEN FOR REGISTRATION NEAR YOU! Start your team and bring your community to get involved!  November 11, Los Angeles CA https://runsignup.com/Race/CA/SantaMonica/LookinForACureLosAngeles November 19, Scottsdale, AZ https://runsignup.com/Race/AZ/Scottsdale/LookinForACureArizona December 9, Dallas FTW TX https://runsignup.com/Race/TX/FortWorth/LookinForACureFortWorth December 10, Houston, TX https://runsignup.com/Race/TX/Houston/LookinForACureHouston January 20, 2024 Orlando FL https://runsignup.com/Race/FL/Orlando/LookinForACureTampa January 21, 2024, Miami FL https://runsignup.com/Race/FL/Miami/LookinForACureMiami Head to our site to register for a 5K Lookin' for a Cure near you for the remainder of the year!! www.lookinforacure.org Subscribe to the newsletter to stay in the know Newsletter link Email contact@acureinsight.org for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or  Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via  PAYPAL OR VENMO or reach out directly to contact@acureinsight.org 

Becky Winslow, BS, PharmD Host and Pharmacogenomics Medical Science Liaison; Behnaz Sarrami, MS, PharmD, Host and Pharmacogenomics Medical Science Liaison; Thierry Dervieux, PharmD, PhD, Chief Scientific Officer at Prometheus Laboratories In this episode of the PGX for Pharmacists Podcast, Dr. Thierry Dervieux, Dr. Behnaz Sarrami, and I discuss Dr. Dervieux's career as a PharmD, PhD, and chief scientific officer who has designed a pharmacogenomics test prescribers may use to optimize biosimilars for autoimmune gastrointestinal diseases. Dr. Dervieux will illustrate to our audience pharmacogenomics' potential beyond Tier 1 and 2 genetic testing by describing the clinical validity and utility of his laboratory's suite of tests in the autoimmune gastrointestinal disease diagnosis and treatment market. Behnaz and I hope this episode will inspire pharmacists interested in pharmacogenomics to think beyond the boxed PGx test most laboratories offer when they think about PGx and consider all the biological systems in which genetics impacts drugs' efficacy and safety. Disclaimer: Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc. Becky Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of any other entity.   Transcription: 1 00:00:06,190 --> 00:00:19,620 You're listening to the Pharmacy podcast Network in a world where one size fits all medications dominate the pharmaceutical industry. 2 00:00:20,079 --> 00:00:24,750 Precision medicine brings a ray of hope for those seeking customized health care. 3 00:00:25,350 --> 00:00:32,830 Pharmacists have a unique opportunity to help people in need of specialized testing to ensure medications work as intended. 4 00:00:33,540 --> 00:00:44,680 Welcome to PGX for pharmacists where we unravel the wonders of precision medicine and its potential to revolutionize the way we approach pharmacy care. 5 00:00:45,169 --> 00:00:52,790 Get ready to uncover the secrets behind pharmacogenomics and how it's transforming lives one genome at a time. 6 00:00:52,799 --> 00:00:53,189 Hello, 7 00:00:53,200 --> 00:00:53,950 everyone. 8 00:00:54,159 --> 00:00:55,080 I'm your host, 9 00:00:55,090 --> 00:00:56,389 Doctor Becky Winslow. 10 00:00:56,409 --> 00:01:09,860 And you're listening to the PGX for Pharmacist podcast that we magazine recognized in 2021 as the ninth most listened to genetics podcasts in the world on the PGX for Pharmacist podcast. 11 00:01:09,870 --> 00:01:16,690 We explore all things pharmacogenomics related and our mission is to educate and advocate for PGX. 12 00:01:16,769 --> 00:01:23,849 We accomplish this mission through exclusive interviews with highly qualified and well experienced pharmacogenomics. 13 00:01:23,860 --> 00:01:29,720 Industry leaders such as today's special guest and my name is Baas Sami, 14 00:01:29,730 --> 00:01:32,739 the co-host of PGX for Pharms podcast, 15 00:01:32,750 --> 00:01:33,860 Pharmacogenomics, 16 00:01:33,870 --> 00:01:36,819 medical science liaison and a mentor to pharmacist. 17 00:01:36,889 --> 00:01:40,239 Connect with us on linkedin and let's get a conversation going. 18 00:01:40,269 --> 00:01:46,720 We want to hear from you and how you're impacting pharmacogenomic stakeholders and what you have learned throughout your journey. 19 00:01:48,510 --> 00:01:49,010 Ok. 20 00:01:49,019 --> 00:01:50,819 So without any further ado, 21 00:01:50,839 --> 00:01:54,769 I'm extremely pleased to introduce to our audience. 22 00:01:54,919 --> 00:01:56,059 Doctor Theory Devo, 23 00:01:57,239 --> 00:02:01,129 the Chief Scientific Officer at Prometheus Laboratories, 24 00:02:01,139 --> 00:02:08,139 and Perme Prometheus Laboratories is a reference clinical laboratory that's focused on the diagnosis, 25 00:02:08,149 --> 00:02:13,330 prognosis and monitoring of immune mediated inflammatory diseases. 26 00:02:13,970 --> 00:02:14,229 So, 27 00:02:14,240 --> 00:02:14,649 thank you, 28 00:02:14,660 --> 00:02:17,759 Doctor De for joining us on the podcast. 29 00:02:17,770 --> 00:02:18,589 Today. 30 00:02:18,600 --> 00:02:23,190 I'm excited to share your and Prometheus's story with our audience. 31 00:02:23,649 --> 00:02:25,630 Um in particular, 32 00:02:25,639 --> 00:02:45,369 I'm excited about you sharing your career journey as a farm D phd and Chief scientific officer and designer of the Predictor PK AD A which is a precision guided dosing test for the optimization of Humira Remicade and their bio cylinders. 33 00:02:46,119 --> 00:02:46,449 So, 34 00:02:46,460 --> 00:03:04,220 one of Bana's and my main goals for this episode of the PGX for Pharmacist podcast is to expand our audience's notion of what a PGX test looks like and to inspire them to think bigger than the traditional box PGX test. 35 00:03:04,229 --> 00:03:08,020 Most of them or most of you are uh familiar with. 36 00:03:09,020 --> 00:03:09,429 So, 37 00:03:09,440 --> 00:03:22,179 Doctor D uh I'd like to start the podcast by having our guests um introduce themselves and elaborate on how you are a pharmacogenomics expert. 38 00:03:23,619 --> 00:03:23,800 Yeah, 39 00:03:23,809 --> 00:03:24,250 thank you, 40 00:03:24,259 --> 00:03:25,759 Becky for having me. 41 00:03:25,770 --> 00:03:26,850 Uh uh Yes. 42 00:03:26,860 --> 00:03:27,289 So I am a, 43 00:03:27,300 --> 00:03:30,820 I am a pharmacist uh with uh a family who is a, 44 00:03:30,830 --> 00:03:33,039 a doctorate in pharmacokinetics. 45 00:03:33,539 --> 00:03:44,520 Uh I completed my studies in France and I came as a postdoc uh fellow uh to work in the United States about 20 years ago to work on the pharmacogenomic of anti cancer agents, 46 00:03:44,929 --> 00:03:49,160 uh primarily uh six Maturin as well as methotrexate. 47 00:03:49,169 --> 00:03:50,550 After my post doc, 48 00:03:50,770 --> 00:03:52,960 uh I moved uh in industry for promet. 49 00:03:53,490 --> 00:04:01,429 So I have a large experience in uh uh the implementation of pharmacogenetics testing in immune mediated inflammatory disease. 50 00:04:01,509 --> 00:04:12,550 Our lab Rome was the first uh clinical laboratory in the United States to offer the fin uh metyl transfer genotyping as well as the thin metabolites. 51 00:04:12,559 --> 00:04:13,029 So, 52 00:04:13,050 --> 00:04:21,989 uh uh of uh of 70 publications in the field and uh I'm very uh very excited to have uh to be on the postcard with you uh uh today. 53 00:04:23,660 --> 00:04:24,220 All right. 54 00:04:24,230 --> 00:04:27,359 So thank you for qualifying yourself as an expert. 55 00:04:27,369 --> 00:04:27,619 So, 56 00:04:27,630 --> 00:04:32,839 let's jump right in and delve into your current PGX work. 57 00:04:32,850 --> 00:04:33,279 So, 58 00:04:33,489 --> 00:04:36,540 if you'll tell us um a little about Prometheus, 59 00:04:36,549 --> 00:04:38,000 specifically, 60 00:04:38,010 --> 00:04:40,350 what is Prometheus's mission? 61 00:04:40,359 --> 00:04:43,799 And how are you guys going about accomplishing your mission? 62 00:04:44,760 --> 00:04:44,980 Yeah, 63 00:04:44,989 --> 00:04:45,700 sure. 64 00:04:45,709 --> 00:04:47,459 Uh So Promet is a, 65 00:04:47,470 --> 00:04:52,790 is a reference uh clinical laboratory based in Southern California in San Diego. 66 00:04:53,230 --> 00:04:56,809 Uh The company has been there for uh over 25 years. 67 00:04:56,820 --> 00:05:03,950 We are uh specialize in the differential diagnosis of autoimmune G I disease uh disorders, 68 00:05:04,059 --> 00:05:06,019 uh gastrointestinal disorder, 69 00:05:06,230 --> 00:05:08,619 uh and inflammatory bowel disease. 70 00:05:08,980 --> 00:05:10,299 And over the years, 71 00:05:10,309 --> 00:05:16,600 we have developed a portfolio of a differentiated solution to facilitate the diagnosis, 72 00:05:16,609 --> 00:05:17,470 the prognosis, 73 00:05:17,480 --> 00:05:18,429 the monitoring, 74 00:05:18,660 --> 00:05:21,910 as well as therapy selection with pharmacogenetics testing, 75 00:05:21,920 --> 00:05:24,730 which we are offering to our clinical laboratory. 76 00:05:24,829 --> 00:05:26,350 And most importantly, 77 00:05:26,410 --> 00:05:27,299 uh recently, 78 00:05:27,309 --> 00:05:35,660 we are uh uh developing some uh uh testing solution with the credit topic care test to optimize treatment to uh biologics. 79 00:05:36,470 --> 00:05:37,130 Ok. 80 00:05:37,140 --> 00:05:37,329 Well, 81 00:05:37,339 --> 00:05:37,450 that, 82 00:05:37,459 --> 00:05:38,049 that's great. 83 00:05:38,059 --> 00:05:46,100 Can you also tell us uh about the Prois Library of Precision Medicine Tests for inflammatory bowel disease for patients? 84 00:05:46,109 --> 00:05:49,230 how they benefit medication therapy management. 85 00:05:49,239 --> 00:05:56,429 Stakeholders across the IB DS patients journey from diagnosis to treatment to disease, 86 00:05:56,440 --> 00:06:02,049 monitoring through remission and how they differ from other lab tests for IBD and his treatments. 87 00:06:02,709 --> 00:06:03,209 Yes. 88 00:06:03,220 --> 00:06:03,369 So, 89 00:06:03,380 --> 00:06:04,399 so we uh our, 90 00:06:04,410 --> 00:06:10,100 our clinical laboratory offers some uh highly specialized test to facilitate the, 91 00:06:10,109 --> 00:06:16,779 the diagnostic of uh to facilitate the differential diagnosis of uh uh inflammatory bowel disease. 92 00:06:16,790 --> 00:06:22,359 So we are following uh testing solution with uh serological testing, 93 00:06:22,529 --> 00:06:23,799 for example, 94 00:06:23,809 --> 00:06:38,410 uh uh piana as as as well as uh macro microbial uh uh antibodies that are present uh uh in Crohn's disease as well as uh over uh auto uh auto antibodies that are present in er colitis. 95 00:06:39,339 --> 00:06:43,684 These are conditions that are uh uh somewhat difficult to treat. 96 00:06:43,704 --> 00:06:49,994 Uh And uh we are uh uh offering those tests to uh help uh gastroenterologist. 97 00:06:50,015 --> 00:06:51,114 Uh uh first of all, 98 00:06:51,125 --> 00:07:03,434 to establish a differential diagnosis of IBD as compared to other uh condition typically uh uh irritable bowel syndrome as well as over gastrointestinal disorder. 99 00:07:03,445 --> 00:07:05,635 When the diagnostic is established, 100 00:07:05,910 --> 00:07:31,839 uh we offer uh testing to uh establish a prognosis where we're gonna in inform the clinician that the patient has a more aggressive uh disease that will require more aggressive treatment where uh we can uh provide the testing solution to initiate uh uh the most appropriate therapy for uh for the patient uh with uh a testing where we are uh basically uh you know, 101 00:07:31,850 --> 00:07:36,559 establish de determining some genotyping with the fit transferal genotyping. 102 00:07:36,570 --> 00:07:37,279 For example, 103 00:07:37,290 --> 00:07:40,250 where we can uh indicate that the patient is, 104 00:07:40,260 --> 00:07:45,079 is likely uh to present with a side effect to those medication. 105 00:07:45,399 --> 00:07:46,170 And once you know, 106 00:07:46,179 --> 00:07:47,799 the the treatment is initiative, 107 00:07:47,809 --> 00:08:16,089 we have a portfolio of solution uh to facilitate the monitoring of the disease of the inflammatory bowel disease as well as the dosing optimization with uh uh the answer test which uh measure blood level uh for uh uh monoclonal antibodies that are indicated in the treatment of IB start with starting with Infliximab Adalimumab as well as uh Tein and vidal. 108 00:08:16,980 --> 00:08:24,040 So we have a comprehensive portfolio to uh to surround the clinician with uh a variety of testing solution. 109 00:08:24,049 --> 00:08:30,250 With our goal being to improve the uh the outcome uh of patients with uh with diabetes. 110 00:08:30,260 --> 00:08:34,520 And I think that the pharmacist has a very important role to play from that perspective. 111 00:08:35,179 --> 00:08:36,039 So theory, 112 00:08:36,049 --> 00:08:40,239 could you elaborate for us more on the predictor test? 113 00:08:40,249 --> 00:08:42,758 Um especially since you designed that test, 114 00:08:42,768 --> 00:08:44,218 we'd really like to know, 115 00:08:44,489 --> 00:08:45,039 um you know, 116 00:08:45,049 --> 00:08:49,638 what did that take and what role does it play in your suite of testing? 117 00:08:51,049 --> 00:08:51,270 Yeah. 118 00:08:51,280 --> 00:08:51,890 Sure. 119 00:08:51,900 --> 00:08:52,510 So the, 120 00:08:52,520 --> 00:08:52,570 the, 121 00:08:52,580 --> 00:08:52,989 the, 122 00:08:53,000 --> 00:08:53,229 the, 123 00:08:53,239 --> 00:08:59,960 the predictor test is uh uh is uh is utilized when the patient is receiving treatment. 124 00:09:00,280 --> 00:09:18,190 It's been speci specifically designed to optimize uh biological uh uh disease modifiers such as Infliximab adalimumab that are co therapies in the treatment of inflammatory bowel disease as well as other immune uh mediated inflammatory. 125 00:09:18,200 --> 00:09:21,549 This is what the test does is to you connect the blood specimen, 126 00:09:22,229 --> 00:09:23,049 uh you know, 127 00:09:23,059 --> 00:09:24,750 with dosing information. 128 00:09:25,039 --> 00:09:41,989 And what we do is to uh uh provide guidance uh to clinician with uh respect of the best dose to give in order to achieve the best the level which is the most consistent with uh uh the disease control that needs to be achieved for the patient. 129 00:09:42,169 --> 00:09:43,729 Typically a vast majority, 130 00:09:43,739 --> 00:09:46,159 about two third of a third to two third, 131 00:09:46,169 --> 00:09:54,669 a third of patient uh tend to be uh uh unresponsive uh to this uh very expensive medication. 132 00:09:54,989 --> 00:09:57,960 Uh Not because they don't have the uh you know, 133 00:09:57,969 --> 00:09:59,289 typically because they have a, 134 00:09:59,299 --> 00:09:59,590 you know, 135 00:09:59,599 --> 00:10:05,599 pharmacokinetic uh suboptimal pharmacokinetic uh that makes them uh you know, 136 00:10:05,609 --> 00:10:09,440 unresponsive because uh not enough drug has been given. 137 00:10:09,450 --> 00:10:18,469 So what we do with a predictor test is to basically estimate the pa the pharmacokinetic uh parameter for the patient. 138 00:10:18,750 --> 00:10:24,729 And from then uh re report the best dose uh to give in order to achieve the, 139 00:10:24,760 --> 00:10:31,570 the level which is consistent with the uh the most uh uh effective disease control to be achieved for the patient. 140 00:10:32,169 --> 00:10:33,059 So we are offering, 141 00:10:33,070 --> 00:10:38,049 we have developed a test for the Infliximab as well as Adalimumab which is Humira, 142 00:10:38,909 --> 00:10:41,309 but these are antimony causes factor. 143 00:10:41,460 --> 00:10:49,549 And we are also developing the test for vidur as well as uh is that are widely used also in the treatment of, 144 00:10:49,559 --> 00:10:51,969 of uh inflammatory bubble disease. 145 00:10:51,979 --> 00:10:52,669 Wow, 146 00:10:52,679 --> 00:10:55,450 uh for MET is a suite of tests. 147 00:10:55,460 --> 00:11:00,940 Goes well beyond um the PGX testing that our audience is most familiar with, 148 00:11:01,299 --> 00:11:08,679 uh which typically only includes snips for cyp genes and some pharmacodynamic genes. 149 00:11:08,690 --> 00:11:31,424 This is really exciting um genes and biomarkers related to immunology are not commonly found in what I call the box PGX tests such as those uh made by large uh laboratory manufacturing companies um where the panel has a set number of genes and uh you know, 150 00:11:31,434 --> 00:11:36,054 it was developed by a larger laboratory for maybe smaller laboratories use. 151 00:11:36,729 --> 00:11:39,010 So my understanding, 152 00:11:39,020 --> 00:11:53,729 having talked with you extensively theory is that immunology has fewer PGX test available because it's actually more difficult say than oncology to research and develop tests. 153 00:11:53,739 --> 00:11:54,119 So, 154 00:11:54,130 --> 00:12:00,729 could you elaborate for our audience on the difficulties that are associated with immunology, 155 00:12:00,739 --> 00:12:05,830 research and developing tests uh for immunology versus say oncology? 156 00:12:06,330 --> 00:12:06,530 Yeah, 157 00:12:06,539 --> 00:12:07,049 sure. 158 00:12:07,059 --> 00:12:09,969 So in uh in immunology, 159 00:12:09,979 --> 00:12:11,590 as compared to oncology, 160 00:12:11,599 --> 00:12:17,169 there is no such a thing such as a somatic mutation where for example, 161 00:12:17,179 --> 00:12:18,429 you're gonna have a behalf, 162 00:12:18,440 --> 00:12:18,659 you know, 163 00:12:18,669 --> 00:12:20,349 that indicates that the patient, 164 00:12:20,679 --> 00:12:20,919 you know, 165 00:12:20,929 --> 00:12:25,239 is likely to benefit or not from some treatment in immunology. 166 00:12:25,250 --> 00:12:26,750 This is far more complicated, 167 00:12:26,760 --> 00:12:28,830 complicated for the reason, 168 00:12:29,239 --> 00:12:31,020 starting with uh the fact that, 169 00:12:31,030 --> 00:12:31,179 you know, 170 00:12:31,190 --> 00:12:36,219 the response to this uh medication uh are multifactorial. 171 00:12:36,260 --> 00:12:37,820 And the fact that uh you know, 172 00:12:37,830 --> 00:12:39,380 the mutation that uh the, 173 00:12:39,390 --> 00:12:39,619 the, 174 00:12:39,630 --> 00:12:45,190 the single nucleotide polymorphism in the GM line which uh uh you know, 175 00:12:45,200 --> 00:12:52,429 can potentially associate with uh with outcome uh uh uh uh a lo in advance, 176 00:12:52,440 --> 00:12:58,359 meaning that uh they're gonna have a weak association uh with a response to those medications. 177 00:12:58,369 --> 00:13:09,609 So there is a necessity in immunology to combine multiple genetic polymorphism together in order to achieve uh some uh performances characteristics that will make uh you know, 178 00:13:09,619 --> 00:13:09,859 the, 179 00:13:09,869 --> 00:13:10,380 the, 180 00:13:10,390 --> 00:13:10,520 the, 181 00:13:10,530 --> 00:13:13,219 the clinician uh you know, 182 00:13:13,419 --> 00:13:15,619 uh order the test and most importantly, 183 00:13:15,630 --> 00:13:15,840 the, 184 00:13:15,849 --> 00:13:16,179 the, 185 00:13:16,190 --> 00:13:17,739 the payer to pay for the test. 186 00:13:17,750 --> 00:13:20,469 So this field has been uh you know, 187 00:13:20,479 --> 00:13:20,679 is, 188 00:13:20,690 --> 00:13:21,705 is moving for, 189 00:13:21,715 --> 00:13:21,994 you know, 190 00:13:22,005 --> 00:13:24,575 there are some tests that are being developed right now. 191 00:13:24,924 --> 00:13:39,034 But the biggest challenge is to be able to achieve again the the threshold of uh of performance that makes the test is variable enough uh to be uh again ordered by the clinician and the utilize uh to the benefit of the patient. 192 00:13:39,659 --> 00:13:41,200 I couldn't agree with you more. 193 00:13:41,210 --> 00:13:53,489 Um I've worked on the payer side or market access side of pharmacogenomics and even uh with a box test for which there's um a lot of research data available, 194 00:13:53,500 --> 00:13:55,119 even with those, 195 00:13:55,130 --> 00:13:59,760 it's sometimes difficult uh to get payers um to see the value. 196 00:13:59,770 --> 00:14:01,640 So I absolutely agree with you. 197 00:14:01,940 --> 00:14:03,679 Um The fact that you guys are, 198 00:14:03,690 --> 00:14:11,789 are uh investing in producing the data necessary says a lot about your laboratory. 199 00:14:11,979 --> 00:14:12,559 Um you know, 200 00:14:12,570 --> 00:14:15,380 and how committed you are to this testing and, 201 00:14:15,390 --> 00:14:17,320 and how you believe in the testing. 202 00:14:18,039 --> 00:14:23,640 So I just want to make sure that our audience recognizes that, 203 00:14:24,359 --> 00:14:24,619 you know, 204 00:14:24,630 --> 00:14:31,820 Prometheus doesn't simply provide tests to determine if drugs for IBD will be effective and safe. 205 00:14:32,190 --> 00:14:36,900 Um And maybe what the dose of the drug should be for the patient, 206 00:14:36,909 --> 00:14:40,219 but you have that whole suite of tests. 207 00:14:40,229 --> 00:14:47,380 Um the diagnostic test for the differential diagnosis all the way through remission. 208 00:14:48,030 --> 00:14:53,390 So can you elaborate you elaborated on it some in the previous question? 209 00:14:53,400 --> 00:15:01,229 But um can you tell us the difference between how you had to actually develop the test? 210 00:15:01,520 --> 00:15:02,530 Um You didn't, 211 00:15:02,539 --> 00:15:03,059 in other words, 212 00:15:03,070 --> 00:15:10,659 purchase a test from another manufacturer with the biomarkers that you include in your testing. 213 00:15:10,669 --> 00:15:16,830 Can you elaborate on how much more difficult it is to to develop a test from scratch? 214 00:15:18,169 --> 00:15:18,320 Yeah, 215 00:15:18,330 --> 00:15:18,659 sure. 216 00:15:18,669 --> 00:15:18,809 I mean, 217 00:15:18,820 --> 00:15:22,070 this is this is challenging for multiple and first of all, 218 00:15:22,080 --> 00:15:23,130 you need to have the, 219 00:15:23,419 --> 00:15:27,450 you need to have a clinical data set available with specimen available. 220 00:15:27,460 --> 00:15:28,159 Uh you know, 221 00:15:28,169 --> 00:15:28,780 in front, 222 00:15:28,859 --> 00:15:29,770 obviously, 223 00:15:29,859 --> 00:15:30,890 available. 224 00:15:31,200 --> 00:15:35,890 Uh So we are leveraging a pro meters a large bi bank of specimen. 225 00:15:36,299 --> 00:15:37,190 Uh as I said, 226 00:15:37,200 --> 00:15:39,719 Prometheus has been founded 25 years ago. 227 00:15:39,729 --> 00:15:40,599 So over the, 228 00:15:40,760 --> 00:15:41,919 the past two decades, 229 00:15:41,929 --> 00:15:54,849 we have been able to assemble a large uh substrate of data and specimen which we are uh uh using to uh uh establish our proof of concept if you will. 230 00:15:54,859 --> 00:16:07,559 And then when we have uh identify some genetic polymorphism that are uh adequately uh associated with uh uh disease outcome and disease progression as well as uh toxicity. 231 00:16:07,969 --> 00:16:11,469 Then we are entering validation phase where we are uh you know, 232 00:16:11,570 --> 00:16:14,789 using validation cohorts where we are again, 233 00:16:14,969 --> 00:16:22,630 combining multiple modalities together uh patient demographic as well as genetic marker together with theological marker. 234 00:16:22,640 --> 00:16:23,190 Actually, 235 00:16:23,500 --> 00:16:27,419 to come up with some Multivariate models that are uh again, 236 00:16:27,429 --> 00:16:39,250 bringing the performances characteristics of the pharmacogenomic test or its combination with our marker to the level where it's supposed to be in the first place to meet uh uh payer. 237 00:16:39,650 --> 00:16:41,190 And uh obviously, 238 00:16:41,200 --> 00:16:41,760 again, 239 00:16:41,770 --> 00:16:45,320 the patient uh to the benefit of the patient and to, 240 00:16:45,330 --> 00:16:46,619 to improve its outcome, 241 00:16:46,739 --> 00:16:47,429 the outcome. 242 00:16:48,340 --> 00:16:53,380 I think what you're describing really is the future of pharmacogenomics. 243 00:16:53,390 --> 00:16:54,599 Um In other words, 244 00:16:54,609 --> 00:17:03,419 not singing out pharmacogenomics as you know the end all and be all in the treatment paradigm. 245 00:17:03,559 --> 00:17:08,040 But using a PGX test in combination with, 246 00:17:08,050 --> 00:17:09,069 like you mentioned, 247 00:17:09,250 --> 00:17:11,160 other serological tests, 248 00:17:11,170 --> 00:17:12,959 maybe other genetic tests. 249 00:17:13,290 --> 00:17:14,890 Um But you know, 250 00:17:14,900 --> 00:17:25,869 I think what we want our audience to really wrap their heads around is that PGX is just a piece of that larger puzzle um from diagnosis to treatment to, 251 00:17:25,880 --> 00:17:26,910 to remission. 252 00:17:27,239 --> 00:17:29,880 So I think you guys are absolutely, 253 00:17:29,890 --> 00:17:31,579 you're already in the future. 254 00:17:31,589 --> 00:17:32,849 In other words, 255 00:17:32,859 --> 00:17:33,130 you know, 256 00:17:33,140 --> 00:17:39,689 you're already providing all these different uh tests um like you mentioned to, 257 00:17:39,699 --> 00:17:44,310 to facilitate from diagnosis to remission to remission. 258 00:17:44,660 --> 00:17:45,520 That's correct. 259 00:17:45,530 --> 00:17:45,829 Yeah. 260 00:17:46,349 --> 00:17:55,089 So um you've given us so much great information about uh the tests that that you guys offer. 261 00:17:55,329 --> 00:18:02,060 Can you explain to our audience um your newest test? 262 00:18:02,069 --> 00:18:03,859 Uh the responder test. 263 00:18:04,150 --> 00:18:12,979 And um what role it will play in the paradigm from the diagnosis of IBD to remission? 264 00:18:14,050 --> 00:18:14,260 Yeah, 265 00:18:14,270 --> 00:18:14,760 sure. 266 00:18:14,770 --> 00:18:15,569 So we, 267 00:18:15,579 --> 00:18:18,069 we are doing things a little bit different than other. 268 00:18:18,079 --> 00:18:19,489 We do believe that uh you know, 269 00:18:19,500 --> 00:18:21,449 the it has to be simple. 270 00:18:21,459 --> 00:18:24,189 Uh uh We can obviously construct some very, 271 00:18:24,199 --> 00:18:33,530 very complex algorithm and there are some tests that do that with a very sophisticated machine learning based tools that are available using neural networks, 272 00:18:33,540 --> 00:18:33,729 you know, 273 00:18:33,739 --> 00:18:34,790 those sorts of things. 274 00:18:34,800 --> 00:18:39,729 But we have taken on a different approach where with the responder test, 275 00:18:39,739 --> 00:18:40,329 we are basically, 276 00:18:40,339 --> 00:18:45,160 we are taking an approach which is very simple to address the first and foremost. 277 00:18:45,170 --> 00:18:53,020 Most important aspect of responding uh predicting response to uh to medication is the pharmacokinetics. 278 00:18:53,280 --> 00:19:03,250 Uh You cannot be responding to a drug if the drug is not given and you obviously cannot respond to a drug if the drug is not metabolized adequately. 279 00:19:03,359 --> 00:19:06,349 And this is what we are doing with the responder test. 280 00:19:06,579 --> 00:19:09,010 We are addressing some uh uh you know, 281 00:19:09,020 --> 00:19:11,630 fundamental issues with those uh biologist, 282 00:19:11,640 --> 00:19:12,410 for example, 283 00:19:12,660 --> 00:19:15,170 uh the anti tumor necrosis factors. 284 00:19:15,180 --> 00:19:15,650 So, 285 00:19:15,750 --> 00:19:19,199 such as uh Infliximab and Adalimumab, 286 00:19:19,209 --> 00:19:23,050 it is well known uh that uh uh those drugs, 287 00:19:23,060 --> 00:19:25,689 first of all are prone to immunization. 288 00:19:25,989 --> 00:19:36,949 Uh Meaning that uh uh the drug itself uh is recognized by the immune system uh and digested by the antigen presenting cells. 289 00:19:36,959 --> 00:19:42,209 If you will uh where you gonna have uh uh an immune uh uh response, 290 00:19:42,380 --> 00:19:56,979 uh mounted a cancer drug to produce uh immunogen that will severely impact its pharmacokinetics where the labels will be inadequate to produce uh the desired uh anti-inflammatory effects. 291 00:19:56,989 --> 00:19:57,150 So, 292 00:19:57,160 --> 00:19:58,890 we are with the risk conductors, 293 00:19:58,900 --> 00:20:01,040 we are combining two things together. 294 00:20:01,189 --> 00:20:07,959 First of all is the genetic test itself which uh predicts the risk of immun immunization. 295 00:20:07,969 --> 00:20:18,010 The name of the test is on HL A uh DQ A 105 ali uh that uh uh promotes the presentation of the, 296 00:20:18,020 --> 00:20:19,130 of the, 297 00:20:19,140 --> 00:20:19,910 of Infliximab, 298 00:20:20,010 --> 00:20:20,750 for example, 299 00:20:20,760 --> 00:20:32,130 to the T cell repertoire in order to uh promote the Ronon expansion and the formation of the anti antibodies together with uh another dimension which is the clearance, 300 00:20:32,140 --> 00:20:33,670 which is as important. 301 00:20:33,949 --> 00:20:36,209 Uh One of the key issue is the, 302 00:20:36,219 --> 00:20:36,770 the, 303 00:20:36,780 --> 00:20:41,239 the monoclonal antibodies and uh such as Infliximab or Adalimumab. 304 00:20:41,329 --> 00:20:42,280 But in fact, 305 00:20:42,290 --> 00:20:45,890 a neon antibodies that those drugs are uh you know, 306 00:20:45,900 --> 00:20:49,010 cleared and consumed uh from the, 307 00:20:49,020 --> 00:20:50,949 from the central compartment if you will, 308 00:20:50,959 --> 00:20:54,520 since we are doing a little bit of uh uh pharmacokinetics here. 309 00:20:54,530 --> 00:20:56,020 And uh uh you know, 310 00:20:56,030 --> 00:21:06,670 if the patient present who is uh a high degree of inflammatory burden is gonna have uh the patient will have a high clearance and that's gonna worsen uh in the, 311 00:21:06,680 --> 00:21:13,939 in the presence again of the HL AD Q A 105 genetic marker that uh associate with uh immunization. 312 00:21:13,949 --> 00:21:16,859 So I but this is a combination of both, 313 00:21:17,199 --> 00:21:19,359 these are the predictive factors of pharmacokinetic, 314 00:21:20,359 --> 00:21:38,209 which we combine together where the patient presenting with a risk of immunization as well as accelerated clearance due to the fact that the patient has high inflammation or due to the fact that they are so intrinsic pharmacokinetic properties that makes that the patient, 315 00:21:38,219 --> 00:21:38,300 you know, 316 00:21:38,310 --> 00:21:39,479 will clear the drug very, 317 00:21:39,489 --> 00:21:40,260 very fast. 318 00:21:40,560 --> 00:21:41,670 For example, 319 00:21:41,680 --> 00:21:46,819 due to the inefficient uh recirculation of the drug itself with the new, 320 00:21:46,869 --> 00:21:46,930 the, 321 00:21:46,939 --> 00:21:50,599 the the in the reticular on the system. 322 00:21:50,920 --> 00:21:51,619 Together, 323 00:21:51,630 --> 00:22:02,109 those patients presenting with uh uh together these uh poor prognostic factor of pharmacokinetic origin will tend to be severely underdose, 324 00:22:02,380 --> 00:22:06,719 will not be responding to the drug uh adequately as and they, 325 00:22:06,729 --> 00:22:10,719 and they probably should in the first place if you are able to address uh you know, 326 00:22:10,729 --> 00:22:12,270 the the the exposure. 327 00:22:12,439 --> 00:22:14,079 So what we do with this test, 328 00:22:14,089 --> 00:22:21,640 we will be able to inform uh the clinic that the patient is at risk of achieving, 329 00:22:21,650 --> 00:22:30,829 of achieving suboptimal pharmacokinetics and therefore being able to adjust the dose uh uh to start with more adequately. 330 00:22:30,839 --> 00:22:38,650 So that the the the proper uh exposure is achieved uh during induction to again to, 331 00:22:38,660 --> 00:22:39,040 to, 332 00:22:39,050 --> 00:22:39,380 to, 333 00:22:39,390 --> 00:22:40,890 to achieve a better outcome. 334 00:22:41,040 --> 00:22:47,270 And I think the pharmacist will have a very important role to play here in terms of absolutely, 335 00:22:47,280 --> 00:22:51,239 that information is priceless in the management of these medications. 336 00:22:51,250 --> 00:22:54,930 So thanks for elaborating on that. 337 00:22:56,010 --> 00:22:59,040 And if I may add in our previous conversation, 338 00:22:59,050 --> 00:23:00,810 uh before the recording of podcast, 339 00:23:00,819 --> 00:23:08,869 we had discussed um you guys' robust platform for collaborating with payers to obtain market access and reimbursements for the test. 340 00:23:09,109 --> 00:23:14,109 But without stealing the Thunder from uh Prometheus market access and reimbursement team, 341 00:23:14,199 --> 00:23:22,619 can you please uh briefly detail how Prometheus has proactively worked with payers to solve the problem. 342 00:23:22,920 --> 00:23:27,349 Um the population health problem by building the evidence payers want, 343 00:23:27,359 --> 00:23:41,170 want to see um about your test before you go to the market and then build the test and then hope the payers will see the value and the result and then that will improve the market access and reimbursement for your um precision medicine test. 344 00:23:42,160 --> 00:23:42,339 Yeah. 345 00:23:42,349 --> 00:23:43,180 So briefly I can, 346 00:23:43,189 --> 00:23:43,579 I'm, 347 00:23:43,589 --> 00:23:46,619 I'm probably not the right person to answer that question. 348 00:23:46,630 --> 00:23:47,369 We have a very, 349 00:23:47,380 --> 00:23:52,400 very efficient market access group uh uh pro meters that does a splendid job. 350 00:23:52,410 --> 00:23:59,780 But uh uh uh what I can tell you that we have an evidence uh uh development plan in place where we, 351 00:23:59,790 --> 00:24:14,000 we are establishing the clinical utility of our testing solution by demonstrating uh the payer value uh with respect of uh patient management and uh uh and the, 352 00:24:14,010 --> 00:24:16,630 and the impact of our technology on the, 353 00:24:16,640 --> 00:24:18,119 on physician behavior. 354 00:24:18,430 --> 00:24:21,319 Uh We have uh uh already uh you know, 355 00:24:21,329 --> 00:24:25,160 commercialized uh two of those tests for which we have initiated, 356 00:24:25,170 --> 00:24:29,040 initiated the Power studies uh that uh uh you know, 357 00:24:29,050 --> 00:24:32,000 already provide uh you know, 358 00:24:32,104 --> 00:24:34,484 differentiated and the value to, 359 00:24:34,494 --> 00:24:35,915 to the payer where we are, 360 00:24:35,925 --> 00:24:36,025 the, 361 00:24:36,035 --> 00:24:46,005 the clinicians are basically using our technology to make treatment decision uh as well as uh some prospective clinicality study which we are initiating, 362 00:24:46,145 --> 00:24:47,555 initiating to. 363 00:24:47,564 --> 00:24:48,574 Um uh again, 364 00:24:48,584 --> 00:24:49,425 demonstrate the, 365 00:24:49,435 --> 00:24:49,915 the, 366 00:24:49,925 --> 00:24:50,244 the, 367 00:24:50,255 --> 00:24:53,594 the payer value you uh uh we can certainly follow up with, 368 00:24:53,604 --> 00:24:58,755 uh you can certainly follow up with our market access group uh uh as appropriate there. 369 00:24:58,765 --> 00:25:00,765 Uh They can fill you with more information. 370 00:25:01,349 --> 00:25:01,589 No, 371 00:25:01,599 --> 00:25:02,520 that totally makes sense. 372 00:25:02,530 --> 00:25:03,310 That totally makes sense. 373 00:25:03,319 --> 00:25:10,890 But um we're excited that you're also farm d So how did you get to this role of outside the box path? 374 00:25:10,900 --> 00:25:11,550 There? 375 00:25:11,640 --> 00:25:17,530 There may be a pharmacist student or pharmacist wanting to switch or transition into a role such as yours, 376 00:25:17,540 --> 00:25:19,609 which is a Chief Scientific Officer. 377 00:25:19,619 --> 00:25:20,609 I want to learn more. 378 00:25:20,619 --> 00:25:23,920 So how would you um can you talk a little bit about that? 379 00:25:24,560 --> 00:25:24,780 Well, 380 00:25:24,790 --> 00:25:26,270 we are clinical laboratories. 381 00:25:26,280 --> 00:25:29,400 So in order to uh uh to be in my role, 382 00:25:29,410 --> 00:25:34,020 you need to have uh uh you need to have expertise in clinical laboratory science. 383 00:25:34,030 --> 00:25:36,140 So for the students is basically, 384 00:25:36,150 --> 00:25:36,300 you know, 385 00:25:36,310 --> 00:25:40,770 to do the family degree and then complete the family degree with uh a doctorate, 386 00:25:40,780 --> 00:25:40,930 you know, 387 00:25:40,939 --> 00:25:44,260 which is uh focus on clinical laboratory science. 388 00:25:44,270 --> 00:25:46,079 So you can achieve uh uh you know, 389 00:25:46,089 --> 00:25:47,640 the all the elements you need to be, 390 00:25:47,650 --> 00:25:48,219 for example, 391 00:25:48,229 --> 00:25:53,189 board certified uh as uh as as medical laboratory director. 392 00:25:53,199 --> 00:25:55,160 So you can uh uh so, 393 00:25:55,170 --> 00:25:55,589 uh yeah, 394 00:25:55,599 --> 00:25:56,030 this is, 395 00:25:56,040 --> 00:25:56,400 this is, 396 00:25:56,410 --> 00:25:57,209 this is uh you know, 397 00:25:57,219 --> 00:25:59,160 a great opportunity I think for pharmacies, 398 00:25:59,170 --> 00:26:10,800 there is an absolute need to uh have the clinical pharmacist provide uh uh drug information to healthcare professional as well as uh assist patient with the monitoring of their disease, 399 00:26:10,810 --> 00:26:15,229 the effectiveness of the therapy and um and uh you know, 400 00:26:15,239 --> 00:26:16,060 monitoring the, 401 00:26:16,069 --> 00:26:20,969 the side effect and the toxicity from uh from those uh those medication. 402 00:26:24,650 --> 00:26:24,959 Well, 403 00:26:24,969 --> 00:26:32,119 the I know our audience is going to have uh additional questions for you. 404 00:26:32,130 --> 00:26:32,540 I mean, 405 00:26:32,989 --> 00:26:35,609 you've provided them with so much great information, 406 00:26:35,619 --> 00:26:44,959 but it's only the beginning of what they could possibly learn um about um the testing that you do for IBD and, 407 00:26:44,969 --> 00:26:46,729 and even your career path. 408 00:26:47,050 --> 00:26:47,530 So, 409 00:26:47,540 --> 00:26:49,300 if you wouldn't mind telling us, 410 00:26:49,310 --> 00:26:51,359 um because we have to wrap up, 411 00:26:51,369 --> 00:26:52,670 unfortunately, 412 00:26:53,150 --> 00:26:55,810 this episode of the podcast, 413 00:26:55,819 --> 00:27:00,250 uh could you tell us how our audience members might be able to contact you directly. 414 00:27:01,260 --> 00:27:01,449 Yeah, 415 00:27:01,459 --> 00:27:07,079 I can be contacted on my uh on my email at TT W at como slab dot com. 416 00:27:07,949 --> 00:27:08,810 All right. 417 00:27:09,069 --> 00:27:09,300 Well, 418 00:27:09,310 --> 00:27:14,290 thank you again so much uh for joining us on this episode. 419 00:27:14,300 --> 00:27:15,290 We really, 420 00:27:15,300 --> 00:27:29,530 really hope that our listeners um ideas of not only what PGX can be but how PGX can be utilized in a comprehensive testing suite. 421 00:27:29,709 --> 00:27:35,670 We really hope that our a our audience will um listen in and learn this information. 422 00:27:36,280 --> 00:27:37,869 Um And to our audience, 423 00:27:37,880 --> 00:27:39,439 thank you for tuning in. 424 00:27:39,449 --> 00:27:42,619 We really hope that you've learned from this episode. 425 00:27:43,130 --> 00:27:46,339 Uh We do a whole lot of PG Xing here on this podcast. 426 00:27:46,349 --> 00:27:48,380 We talk about PGX Science, 427 00:27:48,390 --> 00:27:52,030 clinical application and the business of PGX. 428 00:27:52,260 --> 00:27:54,880 So we'd love to hear about from you. 429 00:27:55,099 --> 00:27:56,479 I love to hear from you. 430 00:27:56,489 --> 00:27:58,439 Um What can we teach you? 431 00:27:58,449 --> 00:28:00,920 What more can we teach you through our podcast? 432 00:28:00,930 --> 00:28:12,349 So please drop us a message on linkedin and let us know and please share this link to this podcast link episode with everyone so they can tune in and listen to the PGX for promises podcast. 433 00:28:12,520 --> 00:28:15,369 Leave us a review on Apple podcast or Spotify. 434 00:28:15,459 --> 00:28:18,130 And you can also visit us on PGX four, 435 00:28:18,140 --> 00:28:22,989 the number four Rx dot com to listen to all our other episodes. 436 00:28:23,000 --> 00:28:23,079 Well, 437 00:28:23,089 --> 00:28:23,790 thank you. 438 00:28:24,199 --> 00:28:28,750 Thanks for your interest in PGX and for spending some time with us. 439 00:28:28,760 --> 00:28:35,670 Please share this podcast and leave us a review on Apple podcasts or Spotify for all of our episodes. 440 00:28:35,680 --> 00:28:39,390 Please visit PGX four Rx dot com. 441 00:28:39,569 --> 00:28:43,380 That's PGX four Rx dot com.  

Explore the realm of pharmacogenomic testing as patients open up about their experiences, sharing stories of both success and tragedy. These courageous guests provide insights into the power of personalized medicine and the crucial lessons learned along the way. A journey from medication struggles to success through pharmacogenomics. A heartbreaking tale of genetic-based medication complications. Navigating emotions while uncovering genetic insights. Triumphs of Personalization: Guests share uplifting accounts of renewed health and life improvements due to pharmacogenomic testing. Learning from Tragedy: Stories underscore the consequences of neglecting genetic factors, advocating for greater awareness. Emotional Resilience: Discussing the psychological challenges in the context of chronic conditions and medication adjustments. Empowering Patients and Providers: Guests stress education and dialogue between patients and medical professionals for informed decisions. Join us as we unravel narratives of strength, hope, and knowledge in pharmacogenomic testing. This episode provides a valuable perspective on the fusion of genetics and healthcare, whether you're a patient, healthcare provider, or simply intrigued by personalized medicine's evolution. Special interviews with Christina Delsoldato, Karen Merrit, Christine Von Raesfeld, and Joanne McIntyre. Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc.

Explore the realm of pharmacogenomic testing as patients open up about their experiences, sharing stories of both success and tragedy. These courageous guests provide insights into the power of personalized medicine and the crucial lessons learned along the way. A journey from medication struggles to success through pharmacogenomics. A heartbreaking tale of genetic-based medication complications. Navigating emotions while uncovering genetic insights. Triumphs of Personalization: Guests share uplifting accounts of renewed health and life improvements due to pharmacogenomic testing. Learning from Tragedy: Stories underscore the consequences of neglecting genetic factors, advocating for greater awareness. Emotional Resilience: Discussing the psychological challenges in the context of chronic conditions and medication adjustments. Empowering Patients and Providers: Guests stress education and dialogue between patients and medical professionals for informed decisions. Join us as we unravel narratives of strength, hope, and knowledge in pharmacogenomic testing. This episode provides a valuable perspective on the fusion of genetics and healthcare, whether you're a patient, healthcare provider, or simply intrigued by personalized medicine's evolution. Special interviews with Christina Delsoldato, Karen Merrit, Christine Von Raesfeld, and Joanne McIntyre. Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc.

Wondering if you should get a biopsy? Wanting to understand more about the biopsy of your eye? Join A Cure in Sight and back again, the wonderful Dr. Basil K Williams to discuss Prognostication of the Eye – A special episode selected and sponsored by Castle Biosciences. Learn about the classes of eye tumors, what newer research tells us, and where research is headed. ANNOUNCEMENTS: 5K SITES ARE OPEN FOR REGISTRATION NEAR YOU! Start your team and bring your community to get involved!  September 23, Denver, CO https://runsignup.com/Race/CO/Denver/LookinForACureDenver November 18, Los Angeles CA https://runsignup.com/Race/CA/SantaMonica/LookinForACureLosAngeles November 19, Phoenix, AZ https://runsignup.com/Race/AZ/Scottsdale/LookinforaCure5k December 9, Dallas FTW TX https://runsignup.com/Race/TX/FortWorth/LookinForACureFortWorth December 10, Houston, TX https://runsignup.com/Race/TX/Houston/LookinForACureHouston January 20, 2024 Orlando FL https://runsignup.com/Race/FL/Orlando/LookinForACureTampa January 21, 2024, Miami FL https://runsignup.com/Race/FL/Miami/LookinForACureMiami Head to our site to register for a 5K Lookin' for a Cure near you for the remainder of the year!! www.lookinforacure.org  REGISTER TODAY for the Eye Believe Survivorship Seminar happening in Seattle, WA, Sept 8-9, 2023! Subscribe to the newsletter to stay in the know Newsletter link Email contact@acureinsight.org for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or  Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via  PAYPAL OR VENMO or reach out directly to contact@acureinsight.org 

DYPD is a gene that provides instructions for making an enzyme called dihydropyrimidine dehydrogenase (DPD). This enzyme plays very important in breaking down a substance called uracil, which is found in our DNA and RNA. Mutations in the DYPD gene can lead to decreased or absent DPD activity, which if you think about it can cause a buildup of uracil in the body.  If someone is DPD deficiency it can make it difficult for the body to process certain chemotherapy drugs and can lead to severe side effects, such as nerve damage, GI problems, and even death. Genetic testing before being placed on a chemo agent, to see if there is a DPD deficiency is vital.  According to Advocates for Universal DPD/DPYD Testing (AUDT), Europe is becoming the standard of care for testing for this gene and only in some selected institutions in the US the testing it being done.  AUDT is made up of a group of patient advocates and medical professionals who are seeking to improve treatment outcomes for patients that are preparing to receive chemotherapy based on fluoropyrimidine drugs. One of the founders of this non-profit organization, AUDT, Karen Merritt is our guest today. She lost her mother in 2014 due to being DPD deficient and after getting her first infusion of 5FU. Karen dedicated herself to advocating and raising awareness about pre-testing for DPD deficiency before fluoropyrimidine chemotherapy administration to reduce unnecessary suffering. Resources: https://test4dpd.org/about-us/ Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc.